[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fsetB-V4nC8konnhjTxaXF2jG9kBMS6Y4QcIjcRXSQW8":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":37,"phaseBuckets":82,"rows":89},"Ipsen",[4],286,false,35,77,64427,15,102,[14,17,20,23,26,29,32,34],{"name":15,"count":16},"Acromegaly",34,{"name":18,"count":19},"Prostate Cancer",21,{"name":21,"count":22},"Cervical Dystonia",11,{"name":24,"count":25},"Neuroendocrine Tumors",9,{"name":27,"count":28},"Muscle Spasticity",7,{"name":30,"count":31},"Spasticity",6,{"name":33,"count":31},"Renal Cell Carcinoma",{"name":35,"count":36},"Advanced Renal Cell Carcinoma",4,[38,43,48,52,57,62,67,71,74,78],{"nctId":39,"briefTitle":40,"date":41,"intervention":42},"NCT04526665","Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC)","2023-06-01","Elafibranor 80mg",{"nctId":44,"briefTitle":45,"date":46,"intervention":47},"NCT06047444","A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Chronic Migraine in Adults","2026-05-21","Botulinum toxin type A",{"nctId":49,"briefTitle":50,"date":51,"intervention":47},"NCT06047457","A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults","2026-05-27",{"nctId":53,"briefTitle":54,"date":55,"intervention":56},"NCT06383403","A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid.","2026-06-26","Elafibranor",{"nctId":58,"briefTitle":59,"date":60,"intervention":61},"NCT05627362","A Study to Assess Safety and Effectiveness of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis.","2026-08-28","Elafibranor 80 mg",{"nctId":63,"briefTitle":64,"date":65,"intervention":66},"NCT04821089","A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Moderate to Severe Upper Facial Lines","2026-08-31","IPN10200",{"nctId":68,"briefTitle":69,"date":70,"intervention":66},"NCT07435428","A Study to Assess the Effectiveness and Safety of IPN10200 Over Time in Adults With Moderate to Severe Wrinkle-like Lines Between the Eyebrows","2026-12-15",{"nctId":72,"briefTitle":73,"date":70,"intervention":66},"NCT07427797","A Study to Assess the Effectiveness and Safety of IPN10200 in Adults With Moderate to Severe Wrinkle-like Lines Between the Eyebrows",{"nctId":75,"briefTitle":76,"date":77,"intervention":56},"NCT06730061","A Study of Elafibranor in Adult Japanese Participants With Primary Biliary Cholangitis (PBC)","2026-12-17",{"nctId":79,"briefTitle":80,"date":81,"intervention":66},"NCT06625060","A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults","2027-01-31",[83,84,85,86,87,88],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[90,163,234,686,709,731,749,767,793,811,832,850,874,898,927,951,1109,1161,1203,1235,1269,1304,1327,1351,1377,1395,1418,1436,1462,1487,1505,1550,1596,1630,1664,1707,1729,1764,1804,1835,1868,1886,1912,1930,1953,1979,1997,2024,2047,2065,2083,2106,2130,2157,2175,2202,2220,2238,2260,2278,2303,2326,2348,2366,2390,2414,2432,2450,2468,2486,2511,2529,2578,2620,2645,2674,2698,2716,2739,2763,2789,2807,2834,2852,2870,2888,2909,2932,2955,2978,2996,3020,3038,3071,3099,3117,3139,3165,3183,3201,3219,3243,3261,3287,3305,3336,3358,3376,3394,3448,3495,3521,3554,3572,3596,3621,3644,3667,3692,3710,3734,3758,3781],{"intervention":66,"totalTrials":31,"cells":91},{"EARLY_PHASE1":92,"PHASE1":95,"PHASE2":97,"PHASE3":141,"PHASE4":159,"NA":161},{"trials":93,"activeCount":94},[],0,{"trials":96,"activeCount":94},[],{"trials":98,"activeCount":36,"soonestReadout":65},[99,111,121,131],{"nctId":79,"briefTitle":80,"status":100,"phases":101,"primaryCompletion":81,"completion":102,"start":103,"enrollment":104,"conditions":105,"interventions":108},"RECRUITING",[85],"2027-10-31","2024-10-10",641,[106,107],"Episodic Migraine","Chronic Migraine",[66,109,110],"IPN10200 dose A","IPN10200 dose B",{"nctId":112,"briefTitle":113,"status":100,"phases":114,"primaryCompletion":115,"completion":115,"start":116,"enrollment":117,"conditions":118,"interventions":119},"NCT04752774","A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Upper Limb Spasticity.",[84,85],"2029-03-30","2021-04-29",240,[30],[66,120],"Dysport",{"nctId":122,"briefTitle":123,"status":100,"phases":124,"primaryCompletion":125,"completion":126,"start":127,"enrollment":128,"conditions":129,"interventions":130},"NCT06937931","A Study of IPN10200 for the Treatment of Cervical Dystonia in Adults",[85],"2027-03-26","2027-11-05","2025-06-30",132,[21],[66],{"nctId":63,"briefTitle":64,"status":132,"phases":133,"primaryCompletion":65,"completion":134,"start":135,"enrollment":136,"conditions":137,"interventions":139},"ACTIVE_NOT_RECRUITING",[84,85],"2027-08-19","2021-04-06",727,[138],"Moderate to Severe Upper Facial Lines",[66,140,120],"IPN10200 Placebo",{"trials":142,"activeCount":158,"soonestReadout":70},[143,151],{"nctId":68,"briefTitle":69,"status":100,"phases":144,"primaryCompletion":70,"completion":145,"start":146,"enrollment":147,"conditions":148,"interventions":150},[86],"2028-10-01","2026-02-18",1300,[149],"Moderate to Severe Glabellar Lines",[66],{"nctId":72,"briefTitle":73,"status":100,"phases":152,"primaryCompletion":70,"completion":153,"start":154,"enrollment":155,"conditions":156,"interventions":157},[86],"2027-07-15","2026-02-27",300,[149],[66],2,{"trials":160,"activeCount":94},[],{"trials":162,"activeCount":94},[],{"intervention":56,"totalTrials":31,"cells":164},{"EARLY_PHASE1":165,"PHASE1":167,"PHASE2":191,"PHASE3":193,"PHASE4":230,"NA":232},{"trials":166,"activeCount":94},[],{"trials":168,"activeCount":94},[169,180],{"nctId":170,"briefTitle":171,"status":172,"phases":173,"primaryCompletion":174,"completion":174,"start":175,"enrollment":176,"conditions":177,"interventions":179},"NCT05543369","Study to Compare the Level of Elafibranor in Blood After Repeat Administration in Japanese and Non-Asian Healthy Participants","COMPLETED",[84],"2023-03-10","2022-09-19",48,[178],"Healthy Volunteers",[56],{"nctId":181,"briefTitle":182,"status":172,"phases":183,"primaryCompletion":184,"completion":185,"start":186,"enrollment":16,"conditions":187,"interventions":189},"NCT05564208","A Study to Evaluate the Effect of Food on the Level of Circulating Elafibranor in Healthy Participants After Intake of a Single Tablet",[84],"2022-12-30","2023-01-14","2022-10-27",[188],"Healthy Participants",[190,190],"elafibranor",{"trials":192,"activeCount":94},[],{"trials":194,"activeCount":36,"soonestReadout":55},[195,205,216,224],{"nctId":196,"briefTitle":197,"status":100,"phases":198,"primaryCompletion":199,"completion":199,"start":200,"enrollment":201,"conditions":202,"interventions":204},"NCT06016842","A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis",[86],"2029-05-31","2023-08-31",276,[203],"Primary Biliary Cholangitis (PBC)",[56],{"nctId":206,"briefTitle":207,"status":100,"phases":208,"primaryCompletion":209,"completion":210,"start":211,"enrollment":212,"conditions":213,"interventions":215},"NCT07387549","A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis",[86],"2031-04-30","2031-05-31","2026-05-14",350,[214],"Primary Sclerosing Cholangitis",[56],{"nctId":75,"briefTitle":76,"status":132,"phases":217,"primaryCompletion":77,"completion":218,"start":219,"enrollment":220,"conditions":221,"interventions":223},[86],"2032-04-08","2025-01-16",18,[222],"Primary Biliary Cholangitis",[56],{"nctId":53,"briefTitle":54,"status":132,"phases":225,"primaryCompletion":55,"completion":55,"start":226,"enrollment":227,"conditions":228,"interventions":229},[86],"2024-07-09",69,[222],[56],{"trials":231,"activeCount":94},[],{"trials":233,"activeCount":94},[],{"intervention":47,"totalTrials":235,"cells":236},46,{"EARLY_PHASE1":237,"PHASE1":239,"PHASE2":251,"PHASE3":384,"PHASE4":617,"NA":657},{"trials":238,"activeCount":94},[],{"trials":240,"activeCount":94},[241],{"nctId":242,"briefTitle":243,"status":172,"phases":244,"primaryCompletion":245,"completion":246,"start":247,"enrollment":248,"conditions":249,"interventions":250},"NCT04970407","A Comparative Study to Evaluate the Effects and Mechanism of Action of Dysport®, Botox® and Xeomin® in the Extensor Digitorum Brevis Model in Healthy Adult Male Participants",[84],"2022-03-16","2022-06-08","2021-07-06",45,[188],[47,47,47],{"trials":252,"activeCount":94},[253,263,274,286,296,306,316,325,334,343,353,363,374],{"nctId":254,"briefTitle":255,"status":172,"phases":256,"primaryCompletion":257,"completion":257,"start":258,"enrollment":259,"conditions":260,"interventions":262},"NCT01357980","Neurogenic Detrusor Overactivity Following Spinal Cord Injury or Multiple Sclerosis",[85],"2013-03","2011-05",47,[261],"Detrusor Muscle Hyperactivity",[47],{"nctId":264,"briefTitle":265,"status":172,"phases":266,"primaryCompletion":267,"completion":268,"start":269,"enrollment":270,"conditions":271,"interventions":273},"NCT03569098","Dysport in Hallux Abducto Valgus (HAV) Phase IIa",[85],"2019-12-17","2020-05-22","2018-06-19",186,[272],"Hallux Abducto Valgus",[47],{"nctId":275,"briefTitle":276,"status":277,"phases":278,"primaryCompletion":279,"completion":280,"start":281,"enrollment":282,"conditions":283,"interventions":285},"NCT00578097","Efficacy and Safety Study of Botulinum Toxin Type-A (Dysport®) in Continent Female Subjects Suffering From Idiopathic Overactive Bladder","TERMINATED",[85],"2009-06","2009-12","2008-02",81,[284],"Overactive Bladder",[47],{"nctId":287,"briefTitle":288,"status":172,"phases":289,"completion":290,"start":291,"enrollment":292,"conditions":293,"interventions":295},"NCT00210444","Efficacy Study of Dysport® in the Treatment of Anal Fissure.",[85],"2006-12","2003-06",168,[294],"Anal Fissure",[47],{"nctId":297,"briefTitle":298,"status":172,"phases":299,"completion":300,"start":301,"enrollment":302,"conditions":303,"interventions":305},"NCT00301665","Efficacy and Safety Study of Dysport® Used for Migraine Prophylaxis",[85],"2005-03","2003-02",138,[304],"Migraine",[47],{"nctId":307,"briefTitle":308,"status":172,"phases":309,"primaryCompletion":310,"completion":310,"start":311,"enrollment":312,"conditions":313,"interventions":315},"NCT00247559","Botulinum Type A Toxin in the Treatment of Lateral Canthal Lines (Crow's Feet)",[85],"2005-04-08","2004-05",221,[314],"Lateral Canthal Lines",[47],{"nctId":317,"briefTitle":318,"status":172,"phases":319,"primaryCompletion":320,"completion":320,"start":300,"enrollment":321,"conditions":322,"interventions":324},"NCT00134810","Study to Assess the Efficacy and Safety of Dysport® in Upper Back Myofascial Pain Syndrome",[85],"2006-05-18",381,[323],"Myofascial Pain Syndromes",[47],{"nctId":326,"briefTitle":327,"status":172,"phases":328,"primaryCompletion":329,"completion":329,"start":330,"enrollment":331,"conditions":332,"interventions":333},"NCT00149240","Botulinum Toxin Type A (Dysport) Associated With Rehabilitation Treatment in Patients With Primary Myofascial Pain Syndrome",[85],"2006-02-02","2005-01",24,[323],[47],{"nctId":335,"briefTitle":336,"status":277,"phases":337,"primaryCompletion":338,"completion":338,"start":339,"enrollment":31,"conditions":340,"interventions":342},"NCT00455637","Which is the Best Dose of Dysport in Helping With Hip Pain for Children With Cerebral Palsy?",[85],"2008-03-17","2007-03",[341],"Cerebral Palsy",[47],{"nctId":344,"briefTitle":345,"status":172,"phases":346,"primaryCompletion":347,"completion":347,"start":348,"enrollment":349,"conditions":350,"interventions":352},"NCT00234507","Study of a Single Administration of 3 Doses of Dysport® for the Treatment of Benign Essential Blepharospasm",[85],"2004-05-25","2003-01",120,[351],"Blepharospasm",[47],{"nctId":354,"briefTitle":355,"status":172,"phases":356,"primaryCompletion":357,"completion":357,"start":358,"enrollment":359,"conditions":360,"interventions":362},"NCT01333397","Safety and Efficacy Study of Dysport RU and Glabellar Lines",[85],"2011-09","2011-03",176,[361],"Glabellar Frown Lines",[47,47],{"nctId":364,"briefTitle":365,"status":172,"phases":366,"primaryCompletion":367,"completion":367,"start":368,"enrollment":369,"conditions":370,"interventions":372},"NCT03663101","Dysport in Post-Surgical Neuralgia",[85],"2019-11-08","2018-10-30",16,[371],"Chronic Scar Pain",[373,47],"Lidocaine",{"nctId":375,"briefTitle":376,"status":277,"phases":377,"primaryCompletion":378,"completion":378,"start":379,"enrollment":380,"conditions":381,"interventions":383},"NCT03598777","Dysport in Vulvodynia Phase II Study",[85],"2021-01-21","2018-06-11",60,[382],"Vulvodynia",[47],{"trials":385,"activeCount":158,"soonestReadout":46},[386,394,405,416,427,437,446,453,463,472,481,490,500,510,520,530,539,547,556,564,570,579,590,599,608],{"nctId":387,"briefTitle":388,"status":172,"phases":389,"primaryCompletion":390,"completion":390,"start":257,"enrollment":391,"conditions":392,"interventions":393},"NCT01753336","Long Term Safety And Effectiveness Of Dysport® In Adults With Cervical Dystonia",[86],"2015-10",112,[21],[47],{"nctId":395,"briefTitle":396,"status":172,"phases":397,"primaryCompletion":398,"completion":398,"start":399,"enrollment":400,"conditions":401,"interventions":404},"NCT01251367","Dysport® Adult Lower Limb Spasticity Follow-on Study",[86],"2015-04","2011-06",352,[402,403],"Post-stroke Spasticity","Spasticity Post-Traumatic Brain Injury",[47],{"nctId":406,"briefTitle":407,"status":277,"phases":408,"primaryCompletion":409,"completion":410,"start":411,"enrollment":412,"conditions":413,"interventions":415},"NCT02660359","Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 2",[86],"2018-11-09","2019-07-04","2016-07-08",258,[414,284],"Urinary Incontinence",[47,47],{"nctId":417,"briefTitle":418,"status":172,"phases":419,"primaryCompletion":420,"completion":421,"start":422,"enrollment":423,"conditions":424,"interventions":426},"NCT02106351","Efficacy And Safety Of Dysport In The Treatment Of Upper Limb Spasticity In Children",[86],"2017-09-21","2018-09-04","2014-04",212,[425],"Upper Limb Spasticity (Altered Skeletal Muscle Performance) in Children",[47],{"nctId":428,"briefTitle":429,"status":172,"phases":430,"completion":431,"start":432,"enrollment":433,"conditions":434,"interventions":436},"NCT00276315","Assessment of Effectiveness and Safety of Dysport® for the Treatment of Hemifacial Spasm",[86],"2007-01","2005-12",332,[435],"Hemifacial Spasm",[47],{"nctId":438,"briefTitle":439,"status":172,"phases":440,"primaryCompletion":441,"completion":441,"start":442,"enrollment":443,"conditions":444,"interventions":445},"NCT00257660","Randomized, Placebo-Controlled Study of AbobotulinumtoxinA (Dysport®) for the Treatment of Cervical Dystonia",[86],"2006-09","2005-10-10",116,[21],[47],{"nctId":49,"briefTitle":50,"status":132,"phases":447,"primaryCompletion":51,"completion":448,"start":449,"enrollment":450,"conditions":451,"interventions":452},[86],"2026-11-06","2023-09-29",751,[106],[47,47,47,47],{"nctId":454,"briefTitle":455,"status":172,"phases":456,"primaryCompletion":457,"completion":457,"start":458,"enrollment":459,"conditions":460,"interventions":462},"NCT01251380","Dysport® Pediatric Lower Limb Spasticity Follow-on Study",[86],"2015-01","2011-10",216,[341,27,461],"Children",[47],{"nctId":464,"briefTitle":465,"status":172,"phases":466,"primaryCompletion":467,"completion":467,"start":468,"enrollment":412,"conditions":469,"interventions":471},"NCT01313312","Dysport® Adult Upper Limb Spasticity Extension Study",[86],"2014-12","2011-11",[470],"Nervous System Disorders",[47],{"nctId":473,"briefTitle":474,"status":277,"phases":475,"primaryCompletion":409,"completion":476,"start":477,"enrollment":478,"conditions":479,"interventions":480},"NCT02660138","Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 1",[86],"2019-02-14","2016-03",227,[414,284],[47,47],{"nctId":482,"briefTitle":483,"status":172,"phases":484,"primaryCompletion":390,"completion":485,"start":398,"enrollment":486,"conditions":487,"interventions":489},"NCT02493946","Efficacy and Safety of Botulinum Toxin Type A Haemagglutinin Complex Next Generation (BTX-A-HAC NG) in Glabellar Lines",[86],"2016-12",600,[488],"Glabellar Lines",[47],{"nctId":491,"briefTitle":492,"status":172,"phases":493,"primaryCompletion":494,"completion":495,"start":496,"enrollment":497,"conditions":498,"interventions":499},"NCT01261611","Study Comparing Short Term Efficacy of Dysport and Dysport NG to Placebo, and to Assess Efficacy and Safety of Dysport NG of Subjects With Cervical Dystonia",[86],"2012-05","2013-06","2011-04",382,[21],[47,47],{"nctId":501,"briefTitle":502,"status":172,"phases":503,"primaryCompletion":504,"completion":505,"start":506,"enrollment":507,"conditions":508,"interventions":509},"NCT01249417","Dysport® Pediatric Lower Limb Spasticity Study",[86],"2014-02","2014-06","2011-07",241,[341,27,461],[47],{"nctId":511,"briefTitle":512,"status":172,"phases":513,"primaryCompletion":514,"completion":515,"start":358,"enrollment":516,"conditions":517,"interventions":519},"NCT01249404","Dysport® Adult Lower Limb Spasticity Study",[86],"2013-12","2014-05",388,[518],"Leg Spasticity",[47],{"nctId":521,"briefTitle":522,"status":277,"phases":523,"primaryCompletion":524,"completion":524,"start":525,"enrollment":526,"conditions":527,"interventions":529},"NCT01682148","Comparing Lower-concentration Dysport Treatment Targeted to the Neuromuscular Junction With Current Clinical Practice",[86],"2015-03","2012-09",100,[528],"Arm Spasticity",[47],{"nctId":531,"briefTitle":532,"status":172,"phases":533,"primaryCompletion":534,"completion":535,"start":398,"enrollment":536,"conditions":537,"interventions":538},"NCT02450526","Dysport in the Treatment of Glabellar Lines in Chinese Subjects",[86],"2016-07","2017-09-06",520,[488],[47,47],{"nctId":540,"briefTitle":541,"status":172,"phases":542,"primaryCompletion":398,"completion":543,"start":457,"enrollment":544,"conditions":545,"interventions":546},"NCT02353871","Efficacy and Safety of Clostridium Botulinum Toxin Type A to Improve Appearance of Moderate to Severe Glabellar Lines",[86],"2015-08",185,[149],[47],{"nctId":548,"briefTitle":549,"status":172,"phases":550,"primaryCompletion":551,"completion":551,"start":552,"enrollment":553,"conditions":554,"interventions":555},"NCT00288509","Open-label Extension Study of AbobotulinumtoxinA (Dysport®) for the Treatment of Cervical Dystonia",[86],"2008-01","2006-02",108,[21],[47],{"nctId":557,"briefTitle":558,"status":172,"phases":559,"primaryCompletion":560,"completion":560,"start":330,"enrollment":8,"conditions":561,"interventions":563},"NCT00246155","Study on the Effects of Botulinum Toxin Type A on Back Muscle in Chronic Low Back Pain",[86],"2005-07-01",[562],"Low Back Pain",[47],{"nctId":44,"briefTitle":45,"status":132,"phases":565,"primaryCompletion":46,"completion":448,"start":566,"enrollment":567,"conditions":568,"interventions":569},[86],"2023-10-12",759,[107],[47,47,47,47],{"nctId":571,"briefTitle":572,"status":172,"phases":573,"primaryCompletion":574,"completion":574,"start":575,"enrollment":576,"conditions":577,"interventions":578},"NCT01313299","Dysport® Adult Upper Limb Spasticity",[86],"2013-09","2011-08",243,[470],[47,47],{"nctId":580,"briefTitle":581,"status":172,"phases":582,"primaryCompletion":583,"completion":584,"start":585,"enrollment":586,"conditions":587,"interventions":589},"NCT00447876","Study to Assess the Efficacy and Safety of Dysport® in the Treatment of Chronic Plantar Fasciitis",[85,86],"2009-01","2009-04","2005-07",40,[588],"Chronic Plantar Fasciitis",[47],{"nctId":591,"briefTitle":592,"status":172,"phases":593,"primaryCompletion":594,"completion":457,"start":595,"enrollment":596,"conditions":597,"interventions":598},"NCT01753310","Efficacy and Safety of DYSPORT® Using 2mL Dilution in Adults With Cervical Dystonia.",[86],"2014-10","2013-01",134,[21],[47],{"nctId":600,"briefTitle":601,"status":172,"phases":602,"primaryCompletion":603,"completion":603,"start":604,"enrollment":605,"conditions":606,"interventions":607},"NCT00246142","A Study of the Combination of Electrical Stimulation and Dysport® in Myofascial Pain Syndrome.",[86],"2007-06-27","2005-04",76,[323],[47],{"nctId":609,"briefTitle":610,"status":172,"phases":611,"primaryCompletion":281,"completion":612,"start":613,"enrollment":614,"conditions":615,"interventions":616},"NCT00447772","Study to Assess the Efficacy and Safety of Dysport® in Cervical Dystonia",[86],"2008-04","2004-10",516,[21],[47],{"trials":618,"activeCount":94},[619,628,637,646],{"nctId":620,"briefTitle":621,"status":172,"phases":622,"completion":623,"start":301,"enrollment":624,"conditions":625,"interventions":627},"NCT00234546","Asian Botulinum Clinical Trial Designed for Early Stroke Spasticity",[87],"2007-10",162,[27,626],"Cerebrovascular Accident",[47],{"nctId":629,"briefTitle":630,"status":172,"phases":631,"primaryCompletion":477,"completion":477,"start":467,"enrollment":632,"conditions":633,"interventions":636},"NCT02321436","Study to Assess Impact of Dysport Injections Early After Stroke on Upper Limb Spasticity Progression",[87],42,[634,635],"Stroke","Upper Limb Spasticity",[47],{"nctId":638,"briefTitle":639,"status":172,"phases":640,"primaryCompletion":641,"completion":641,"start":642,"enrollment":643,"conditions":644,"interventions":645},"NCT00216411","Effects on Quality of Life Following Dysport Treatment in Post-stroke Spasticity of the Arm",[87],"2006-07-20","2004-11",96,[626,27],[47],{"nctId":647,"briefTitle":648,"status":172,"phases":649,"primaryCompletion":650,"completion":651,"start":652,"enrollment":653,"conditions":654,"interventions":656},"NCT02969356","Study to Evaluate Effects of DYSPORT® Injected in Lower and Upper Limb Combined With Guided Self-Rehabilitation Contract (GSC)",[87],"2018-04-26","2018-07","2016-12-18",157,[655],"Spastic Hemiparesis",[47],{"trials":658,"activeCount":94},[659,669,677],{"nctId":660,"briefTitle":661,"status":172,"phases":662,"primaryCompletion":663,"completion":664,"start":665,"enrollment":666,"conditions":667,"interventions":668},"NCT01753349","Phase IV-Cervical Dystonia-INTEREST IN CD2",[],"2017-09","2017-09-25","2012-12",1050,[21],[47],{"nctId":670,"briefTitle":671,"status":172,"phases":672,"primaryCompletion":673,"completion":673,"start":422,"enrollment":270,"conditions":674,"interventions":676},"NCT02020980","RELIEF Study: Lower Limb Pain Relief After Injection Cycles in Adults Suffering From Lower Limb Spasticity Following Stroke",[],"2018-03-05",[675],"Lower Limb Spasticity",[47],{"nctId":678,"briefTitle":679,"status":172,"phases":680,"primaryCompletion":681,"completion":681,"start":682,"enrollment":683,"conditions":684,"interventions":685},"NCT03017729","Effectiveness and Safety of Dysport® (abobotulinumtoxinA) in Paediatric Lower Limb Spasticity",[],"2020-11-30","2017-02-10",242,[675],[47],{"intervention":42,"totalTrials":687,"cells":688},1,{"EARLY_PHASE1":689,"PHASE1":691,"PHASE2":693,"PHASE3":695,"PHASE4":705,"NA":707},{"trials":690,"activeCount":94},[],{"trials":692,"activeCount":94},[],{"trials":694,"activeCount":94},[],{"trials":696,"activeCount":687,"soonestReadout":41},[697],{"nctId":39,"briefTitle":40,"status":132,"phases":698,"primaryCompletion":41,"completion":699,"start":700,"enrollment":701,"conditions":702,"interventions":704},[86],"2028-12-01","2020-09-24",161,[703],"Primary Biliary Cirrhosis",[42],{"trials":706,"activeCount":94},[],{"trials":708,"activeCount":94},[],{"intervention":120,"totalTrials":158,"cells":710},{"EARLY_PHASE1":711,"PHASE1":713,"PHASE2":715,"PHASE3":725,"PHASE4":727,"NA":729},{"trials":712,"activeCount":94},[],{"trials":714,"activeCount":94},[],{"trials":716,"activeCount":158,"soonestReadout":65},[717,721],{"nctId":112,"briefTitle":113,"status":100,"phases":718,"primaryCompletion":115,"completion":115,"start":116,"enrollment":117,"conditions":719,"interventions":720},[84,85],[30],[66,120],{"nctId":63,"briefTitle":64,"status":132,"phases":722,"primaryCompletion":65,"completion":134,"start":135,"enrollment":136,"conditions":723,"interventions":724},[84,85],[138],[66,140,120],{"trials":726,"activeCount":94},[],{"trials":728,"activeCount":94},[],{"trials":730,"activeCount":94},[],{"intervention":109,"totalTrials":687,"cells":732},{"EARLY_PHASE1":733,"PHASE1":735,"PHASE2":737,"PHASE3":743,"PHASE4":745,"NA":747},{"trials":734,"activeCount":94},[],{"trials":736,"activeCount":94},[],{"trials":738,"activeCount":687,"soonestReadout":81},[739],{"nctId":79,"briefTitle":80,"status":100,"phases":740,"primaryCompletion":81,"completion":102,"start":103,"enrollment":104,"conditions":741,"interventions":742},[85],[106,107],[66,109,110],{"trials":744,"activeCount":94},[],{"trials":746,"activeCount":94},[],{"trials":748,"activeCount":94},[],{"intervention":110,"totalTrials":687,"cells":750},{"EARLY_PHASE1":751,"PHASE1":753,"PHASE2":755,"PHASE3":761,"PHASE4":763,"NA":765},{"trials":752,"activeCount":94},[],{"trials":754,"activeCount":94},[],{"trials":756,"activeCount":687,"soonestReadout":81},[757],{"nctId":79,"briefTitle":80,"status":100,"phases":758,"primaryCompletion":81,"completion":102,"start":103,"enrollment":104,"conditions":759,"interventions":760},[85],[106,107],[66,109,110],{"trials":762,"activeCount":94},[],{"trials":764,"activeCount":94},[],{"trials":766,"activeCount":94},[],{"intervention":768,"totalTrials":687,"cells":769},"IPN60300",{"EARLY_PHASE1":770,"PHASE1":772,"PHASE2":774,"PHASE3":787,"PHASE4":789,"NA":791},{"trials":771,"activeCount":94},[],{"trials":773,"activeCount":94},[],{"trials":775,"activeCount":687,"soonestReadout":780},[776],{"nctId":777,"briefTitle":778,"status":100,"phases":779,"primaryCompletion":780,"completion":780,"start":781,"enrollment":782,"conditions":783,"interventions":786},"NCT07213817","A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours",[84,85],"2028-10-30","2025-12-05",114,[784,785],"Locally Advanced Solid Tumor","Metastatic Solid Tumor",[768],{"trials":788,"activeCount":94},[],{"trials":790,"activeCount":94},[],{"trials":792,"activeCount":94},[],{"intervention":140,"totalTrials":687,"cells":794},{"EARLY_PHASE1":795,"PHASE1":797,"PHASE2":799,"PHASE3":805,"PHASE4":807,"NA":809},{"trials":796,"activeCount":94},[],{"trials":798,"activeCount":94},[],{"trials":800,"activeCount":687,"soonestReadout":65},[801],{"nctId":63,"briefTitle":64,"status":132,"phases":802,"primaryCompletion":65,"completion":134,"start":135,"enrollment":136,"conditions":803,"interventions":804},[84,85],[138],[66,140,120],{"trials":806,"activeCount":94},[],{"trials":808,"activeCount":94},[],{"trials":810,"activeCount":94},[],{"intervention":61,"totalTrials":687,"cells":812},{"EARLY_PHASE1":813,"PHASE1":815,"PHASE2":817,"PHASE3":826,"PHASE4":828,"NA":830},{"trials":814,"activeCount":94},[],{"trials":816,"activeCount":94},[],{"trials":818,"activeCount":687,"soonestReadout":60},[819],{"nctId":58,"briefTitle":59,"status":132,"phases":820,"primaryCompletion":60,"completion":60,"start":821,"enrollment":822,"conditions":823,"interventions":824},[85],"2022-12-29",68,[214],[61,825],"Elafibranor 120 mg",{"trials":827,"activeCount":94},[],{"trials":829,"activeCount":94},[],{"trials":831,"activeCount":94},[],{"intervention":825,"totalTrials":687,"cells":833},{"EARLY_PHASE1":834,"PHASE1":836,"PHASE2":838,"PHASE3":844,"PHASE4":846,"NA":848},{"trials":835,"activeCount":94},[],{"trials":837,"activeCount":94},[],{"trials":839,"activeCount":687,"soonestReadout":60},[840],{"nctId":58,"briefTitle":59,"status":132,"phases":841,"primaryCompletion":60,"completion":60,"start":821,"enrollment":822,"conditions":842,"interventions":843},[85],[214],[61,825],{"trials":845,"activeCount":94},[],{"trials":847,"activeCount":94},[],{"trials":849,"activeCount":94},[],{"intervention":851,"totalTrials":687,"cells":852},"IPN01203",{"EARLY_PHASE1":853,"PHASE1":855,"PHASE2":857,"PHASE3":868,"PHASE4":870,"NA":872},{"trials":854,"activeCount":94},[],{"trials":856,"activeCount":94},[],{"trials":858,"activeCount":687,"soonestReadout":863},[859],{"nctId":860,"briefTitle":861,"status":100,"phases":862,"primaryCompletion":863,"completion":863,"start":864,"enrollment":12,"conditions":865,"interventions":867},"NCT07213830","A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Adults With Locally Advanced or Metastatic Solid Tumours Exposed to Immune Checkpoint Inhibitor Therapies",[84,85],"2032-07-14","2026-02-06",[866,785],"Advanced Solid Tumor",[851],{"trials":869,"activeCount":94},[],{"trials":871,"activeCount":94},[],{"trials":873,"activeCount":94},[],{"intervention":875,"totalTrials":687,"cells":876},"IPN01195",{"EARLY_PHASE1":877,"PHASE1":879,"PHASE2":881,"PHASE3":892,"PHASE4":894,"NA":896},{"trials":878,"activeCount":94},[],{"trials":880,"activeCount":94},[],{"trials":882,"activeCount":687,"soonestReadout":887},[883],{"nctId":884,"briefTitle":885,"status":100,"phases":886,"primaryCompletion":887,"completion":887,"start":888,"enrollment":889,"conditions":890,"interventions":891},"NCT06833008","A Study to Assess a New Medicine Called IPN01195 When Administered Alone in Adults With Advanced Solid Tumours",[84,85],"2028-10-03","2025-03-14",85,[866],[875],{"trials":893,"activeCount":94},[],{"trials":895,"activeCount":94},[],{"trials":897,"activeCount":94},[],{"intervention":899,"totalTrials":687,"cells":900},"IPN01194",{"EARLY_PHASE1":901,"PHASE1":903,"PHASE2":905,"PHASE3":921,"PHASE4":923,"NA":925},{"trials":902,"activeCount":94},[],{"trials":904,"activeCount":94},[],{"trials":906,"activeCount":687,"soonestReadout":911},[907],{"nctId":908,"briefTitle":909,"status":132,"phases":910,"primaryCompletion":911,"completion":911,"start":912,"enrollment":913,"conditions":914,"interventions":920},"NCT06305247","A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours",[84,85],"2028-03-20","2024-04-03",36,[915,916,917,918,919],"Melanoma","Head and Neck Squamous Cell Carcinoma","Pancreatic Ductal Adenocarcinoma","Colorectal Cancer","Solid Tumor",[899,899],{"trials":922,"activeCount":94},[],{"trials":924,"activeCount":94},[],{"trials":926,"activeCount":94},[],{"intervention":928,"totalTrials":687,"cells":929},"Tovorafenib",{"EARLY_PHASE1":930,"PHASE1":932,"PHASE2":943,"PHASE3":945,"PHASE4":947,"NA":949},{"trials":931,"activeCount":94},[],{"trials":933,"activeCount":687,"soonestReadout":938},[934],{"nctId":935,"briefTitle":936,"status":100,"phases":937,"primaryCompletion":938,"completion":938,"start":939,"enrollment":31,"conditions":940,"interventions":942},"NCT07441707","A Study to Assess a Medicine Called Tovorafenib in Japanese Children and Young Adults With Brain Tumours",[84],"2030-07-31","2026-03-03",[941],"Low-grade Glioma",[928],{"trials":944,"activeCount":94},[],{"trials":946,"activeCount":94},[],{"trials":948,"activeCount":94},[],{"trials":950,"activeCount":94},[],{"intervention":952,"totalTrials":11,"cells":953},"lanreotide",{"EARLY_PHASE1":954,"PHASE1":956,"PHASE2":958,"PHASE3":988,"PHASE4":1078,"NA":1107},{"trials":955,"activeCount":94},[],{"trials":957,"activeCount":94},[],{"trials":959,"activeCount":94},[960,969,978],{"nctId":961,"briefTitle":962,"status":277,"phases":963,"primaryCompletion":964,"completion":964,"start":457,"enrollment":965,"conditions":966,"interventions":968},"NCT02365584","Quality of Life in Patients With Inoperable Malignant Bowel Obstruction",[85],"2018-01-16",43,[967],"Intestinal Obstruction",[952],{"nctId":970,"briefTitle":971,"status":972,"phases":973,"primaryCompletion":974,"completion":974,"start":975,"enrollment":94,"conditions":976,"interventions":977},"NCT00517491","Study to Evaluate Patients With Acromegaly Treated With Lanreotide Autogel (Somatuline ATG)","WITHDRAWN",[85],"2008-12","2008-05",[15],[952],{"nctId":979,"briefTitle":980,"status":172,"phases":981,"primaryCompletion":982,"completion":982,"start":983,"enrollment":984,"conditions":985,"interventions":987},"NCT00326469","Efficacy and Safety of Lanreotide Autogel in Tumour Stabilization of Patients With Progressive Neuroendocrine Tumours",[85],"2009-11","2006-05",30,[986],"Neuroendocrine Tumours",[952],{"trials":989,"activeCount":94},[990,1000,1012,1022,1032,1040,1050,1059,1069],{"nctId":991,"briefTitle":992,"status":172,"phases":993,"primaryCompletion":994,"completion":995,"start":996,"enrollment":632,"conditions":997,"interventions":999},"NCT00891371","Lanreotide Autogel in the Symptomatic Treatment of Refractory Diarrhea",[85,86],"2012-08","2013-08","2009-07",[998],"Diarrhea",[952],{"nctId":1001,"briefTitle":1002,"status":172,"phases":1003,"primaryCompletion":1004,"completion":1004,"start":1005,"enrollment":1006,"conditions":1007,"interventions":1010},"NCT00216372","Efficacy and Safety of Lanreotide Microparticles as Palliative Treatment in Peritoneal Carcinomatosis",[86],"2008-10","2003-09",80,[967,1008,1009],"Carcinoma","Peritoneal Neoplasms",[1011],"Lanreotide",{"nctId":1013,"briefTitle":1014,"status":172,"phases":1015,"primaryCompletion":1016,"completion":1016,"start":1017,"enrollment":1018,"conditions":1019,"interventions":1021},"NCT00353496","Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine Tumours",[86],"2013-04","2006-06",264,[1020],"Endocrine Tumors",[952],{"nctId":1023,"briefTitle":1024,"status":277,"phases":1025,"primaryCompletion":1026,"completion":1026,"start":1027,"enrollment":9,"conditions":1028,"interventions":1030},"NCT02683941","Efficacy and Safety of Lanreotide Autogel\u002F Depot 120 mg vs. Placebo in Subjects With Lung Neuroendocrine Tumours",[86],"2020-02-28","2017-03-06",[1029],"Neuroendocrine Tumors in Lung",[1011,1031],"Best Supportive Care",{"nctId":1033,"briefTitle":1034,"status":172,"phases":1035,"primaryCompletion":1036,"completion":1036,"start":1037,"enrollment":553,"conditions":1038,"interventions":1039},"NCT00234572","Efficacy and Safety Study of Varying Doses of Lanreotide Autogel in Patients With Acromegaly",[85,86],"2003-01-03","2000-05",[15],[1011],{"nctId":1041,"briefTitle":1042,"status":172,"phases":1043,"primaryCompletion":1044,"completion":1044,"start":1045,"enrollment":1046,"conditions":1047,"interventions":1049},"NCT00842348","Study of Lanreotide Autogel 120 mg in Patients With Non-functioning Entero- Pancreatic Endocrine Tumour",[86],"2015-12","2009-02",89,[1048],"Non Functioning Entero-pancreatic Endocrine Tumour",[952],{"nctId":1051,"briefTitle":1052,"status":172,"phases":1053,"primaryCompletion":1054,"completion":1054,"start":1055,"enrollment":1056,"conditions":1057,"interventions":1058},"NCT00210457","Efficacy and Safety of Lanreotide Autogel (60, 90 or 120 mg) in Acromegalic Patients",[86],"2002-07-15","2000-09",63,[15],[1011],{"nctId":1060,"briefTitle":1061,"status":172,"phases":1062,"primaryCompletion":1063,"completion":1044,"start":1064,"enrollment":1065,"conditions":1066,"interventions":1068},"NCT00774930","An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome",[86],"2013-05","2009-05",115,[1067],"Carcinoid Syndrome",[1011],{"nctId":1070,"briefTitle":1071,"status":172,"phases":1072,"primaryCompletion":1004,"completion":1004,"start":1073,"enrollment":1074,"conditions":1075,"interventions":1076},"NCT00383708","Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients",[86],"2006-10",125,[15],[952,1077],"Pegvisomant",{"trials":1079,"activeCount":94},[1080,1089,1099],{"nctId":1081,"briefTitle":1082,"status":172,"phases":1083,"primaryCompletion":1084,"completion":1084,"start":1085,"enrollment":1086,"conditions":1087,"interventions":1088},"NCT00216398","Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LAR",[87],"2006-06-22","2004-06",8,[15],[1011],{"nctId":1090,"briefTitle":1091,"status":172,"phases":1092,"primaryCompletion":1093,"completion":1093,"start":1094,"enrollment":1095,"conditions":1096,"interventions":1098},"NCT00681187","Somatuline Autogel Preference and Health Economy Study",[87],"2010-08","2008-06",26,[1097],"Neuroendocrine Tumour With Carcinoid Symptoms",[952],{"nctId":1100,"briefTitle":1101,"status":172,"phases":1102,"primaryCompletion":1103,"completion":1103,"start":1104,"enrollment":984,"conditions":1105,"interventions":1106},"NCT00149188","Somatuline Autogel: Acromegaly Self\u002FPartner Injection Study",[87],"2005-08-24","2004-02",[15],[1011],{"trials":1108,"activeCount":94},[],{"intervention":1110,"totalTrials":36,"cells":1111},"Lanreotide autogel 120 mg",{"EARLY_PHASE1":1112,"PHASE1":1114,"PHASE2":1116,"PHASE3":1141,"PHASE4":1150,"NA":1159},{"trials":1113,"activeCount":94},[],{"trials":1115,"activeCount":94},[],{"trials":1117,"activeCount":94},[1118,1130],{"nctId":1119,"briefTitle":1120,"status":172,"phases":1121,"primaryCompletion":1122,"completion":1123,"start":1124,"enrollment":1125,"conditions":1126,"interventions":1129},"NCT02651987","Efficacy and Safety Study in Pancreatic or Midgut Neuroendocrine Tumours Having Progressed Radiologically While Previously Treated With Lanreotide Autogel® 120 mg",[85],"2019-10-16","2019-10-24","2015-12-15",99,[1127,1128],"Pancreatic Tumours","Midgut Neuroendocrine Tumours",[1110],{"nctId":1131,"briefTitle":1132,"status":172,"phases":1133,"primaryCompletion":485,"completion":1134,"start":594,"enrollment":1135,"conditions":1136,"interventions":1138},"NCT02231762","Combination of Lanreotide Autogel 120mg and Temozolomide in Progressive GEP-NET",[85],"2017-06",57,[1137],"Gastroenteropancreatic Neuroendocrine Tumors",[1139,1140],"Lanreotide Autogel 120 mg","Temozolomide",{"trials":1142,"activeCount":94},[1143],{"nctId":1144,"briefTitle":1145,"status":172,"phases":1146,"primaryCompletion":1147,"completion":1147,"start":975,"enrollment":553,"conditions":1148,"interventions":1149},"NCT00690898","Lanreotide as Primary Treatment for Acromegalic Patients With Pituitary Gland Macroadenoma",[86],"2012-02",[15],[1110],{"trials":1151,"activeCount":94},[1152],{"nctId":1153,"briefTitle":1154,"status":172,"phases":1155,"primaryCompletion":257,"completion":1063,"start":1004,"enrollment":1156,"conditions":1157,"interventions":1158},"NCT00701363","Study to Assess the Efficacy of an Extended Injection Interval Schedule of Lanreotide Autogel in Acromegalic Subjects",[87],124,[15],[1139],{"trials":1160,"activeCount":94},[],{"intervention":1162,"totalTrials":1163,"cells":1164},"EGb 761®",3,{"EARLY_PHASE1":1165,"PHASE1":1167,"PHASE2":1169,"PHASE3":1178,"PHASE4":1189,"NA":1201},{"trials":1166,"activeCount":94},[],{"trials":1168,"activeCount":94},[],{"trials":1170,"activeCount":94},[1171],{"nctId":1172,"briefTitle":1173,"status":277,"phases":1174,"primaryCompletion":612,"completion":612,"start":585,"enrollment":586,"conditions":1175,"interventions":1177},"NCT00500500","Effect of EGb 761® on Patients With Mild to Moderate Alzheimer's Disease",[85],[1176],"Alzheimer Disease",[1162],{"trials":1179,"activeCount":94},[1180],{"nctId":1181,"briefTitle":1182,"status":172,"phases":1183,"completion":1184,"start":1185,"enrollment":259,"conditions":1186,"interventions":1188},"NCT00276341","Study on the Effectiveness of EGb 761® vs Placebo Used for Cognitive Impairment in Patients With Multiple Sclerosis",[86],"2005-12-08","2003-08-26",[1187],"Multiple Sclerosis, Relapsing-Remitting",[1162],{"trials":1190,"activeCount":94},[1191],{"nctId":1192,"briefTitle":1193,"status":172,"phases":1194,"primaryCompletion":982,"completion":982,"start":1195,"enrollment":1196,"conditions":1197,"interventions":1200},"NCT00276510","A Study of EGb 761® (Tanakan®) in Dementia of Alzheimer Type Onset in Patients Suffering From Memory Complaints",[87],"2002-02",2878,[1198,1199],"Memory Disorders, Age-Related","Retention Disorders, Cognitive",[1162],{"trials":1202,"activeCount":94},[],{"intervention":1204,"totalTrials":158,"cells":1205},"Diosmectite",{"EARLY_PHASE1":1206,"PHASE1":1208,"PHASE2":1219,"PHASE3":1221,"PHASE4":1223,"NA":1233},{"trials":1207,"activeCount":94},[],{"trials":1209,"activeCount":94},[1210],{"nctId":1211,"briefTitle":1212,"status":172,"phases":1213,"primaryCompletion":1214,"completion":1214,"start":1215,"enrollment":8,"conditions":1216,"interventions":1218},"NCT03045926","Chronic Administration of Diosmectite (SMECTA®) in Subjects With Chronic Diarrhoea",[84],"2017-05-09","2016-08",[1217],"Chronic Functional Diarrhea of Unknown Origin",[1204],{"trials":1220,"activeCount":94},[],{"trials":1222,"activeCount":94},[],{"trials":1224,"activeCount":94},[1225],{"nctId":1226,"briefTitle":1227,"status":172,"phases":1228,"completion":1229,"start":330,"enrollment":1230,"conditions":1231,"interventions":1232},"NCT00276328","Study to Evaluate Smecta® vs Placebo on the Time to Recovery Following an Acute Diarrhoea Episode in Adults",[87],"2006-07",346,[998],[1204],{"trials":1234,"activeCount":94},[],{"intervention":1236,"totalTrials":158,"cells":1237},"lanreotide acetate",{"EARLY_PHASE1":1238,"PHASE1":1240,"PHASE2":1242,"PHASE3":1244,"PHASE4":1257,"NA":1267},{"trials":1239,"activeCount":94},[],{"trials":1241,"activeCount":94},[],{"trials":1243,"activeCount":94},[],{"trials":1245,"activeCount":94},[1246],{"nctId":1247,"briefTitle":1248,"status":172,"phases":1249,"primaryCompletion":1250,"completion":1251,"start":594,"enrollment":1252,"conditions":1253,"interventions":1254},"NCT02493517","Efficacy and Safety of Lanreotide Autogel® 60, 90 or 120 mg With Lanreotide 40 mg Prolonged Release (PR) in Acromegaly",[86],"2016-11","2017-02-16",128,[15],[1255,1256],"Lanreotide Autogel®","Lanreotide Acetate",{"trials":1258,"activeCount":94},[1259],{"nctId":1260,"briefTitle":1261,"status":172,"phases":1262,"primaryCompletion":1134,"completion":1134,"start":515,"enrollment":1263,"conditions":1264,"interventions":1266},"NCT02075606","Circulating Tumour Cells in Somatuline Autogel Treated NeuroEndocrine Tumours Patients",[87],50,[1265],"NeuroEndocrine Tumours",[1236],{"trials":1268,"activeCount":94},[],{"intervention":1270,"totalTrials":158,"cells":1271},"PEG 4000",{"EARLY_PHASE1":1272,"PHASE1":1274,"PHASE2":1276,"PHASE3":1278,"PHASE4":1290,"NA":1302},{"trials":1273,"activeCount":94},[],{"trials":1275,"activeCount":94},[],{"trials":1277,"activeCount":94},[],{"trials":1279,"activeCount":94},[1280],{"nctId":1281,"briefTitle":1282,"status":172,"phases":1283,"primaryCompletion":1284,"completion":1284,"start":604,"enrollment":1285,"conditions":1286,"interventions":1288},"NCT00255372","To Determine the Effect of Forlax® Treatment in Children With Chronic Constipation Who May Also Suffer From Soiling\u002F Faecal Incontinence.",[86],"2008-05-20",88,[1287],"Chronic Constipation",[1270,1289],"Lactulose active and Lactulose placebo",{"trials":1291,"activeCount":94},[1292],{"nctId":1293,"briefTitle":1294,"status":172,"phases":1295,"completion":1296,"start":1297,"enrollment":1298,"conditions":1299,"interventions":1301},"NCT00276354","Study of Long-term Use of Forlax® in Elderly Patients With Chronic Constipation",[87],"2001-11-20","1999-12",246,[1300],"Constipation",[1270],{"trials":1303,"activeCount":94},[],{"intervention":1305,"totalTrials":687,"cells":1306},"Nutropin [Somatropin (rDNA origin) for injection]",{"EARLY_PHASE1":1307,"PHASE1":1309,"PHASE2":1311,"PHASE3":1313,"PHASE4":1315,"NA":1325},{"trials":1308,"activeCount":94},[],{"trials":1310,"activeCount":94},[],{"trials":1312,"activeCount":94},[],{"trials":1314,"activeCount":94},[],{"trials":1316,"activeCount":94},[1317],{"nctId":1318,"briefTitle":1319,"status":972,"phases":1320,"primaryCompletion":1321,"completion":1321,"start":1063,"enrollment":94,"conditions":1322,"interventions":1324},"NCT01438801","Predictive Value of the Insulin-like Growth Factor-1 (IGF-1) Generation Test for the Growth Response to Growth Hormone Treatment (PRED-IGF)",[87],"2013-05-31",[1323],"Idiopathic Short Stature",[1305],{"trials":1326,"activeCount":94},[],{"intervention":1328,"totalTrials":687,"cells":1329},"Triptorelin 11.25 mg",{"EARLY_PHASE1":1330,"PHASE1":1332,"PHASE2":1334,"PHASE3":1336,"PHASE4":1338,"NA":1349},{"trials":1331,"activeCount":94},[],{"trials":1333,"activeCount":94},[],{"trials":1335,"activeCount":94},[],{"trials":1337,"activeCount":94},[],{"trials":1339,"activeCount":94},[1340],{"nctId":1341,"briefTitle":1342,"status":172,"phases":1343,"primaryCompletion":1344,"completion":1344,"start":1345,"enrollment":1346,"conditions":1347,"interventions":1348},"NCT01753297","A Study of Immediate 9 Months Adjuvant Hormone Therapy With Triptorelin 11.25 mg Versus Active Surveillance After Radical Prostatectomy in High Risk Prostate Cancer Patients.",[87],"2019-09-09","2012-12-11",226,[18],[1328],{"trials":1350,"activeCount":94},[],{"intervention":1352,"totalTrials":687,"cells":1353},"Smecta",{"EARLY_PHASE1":1354,"PHASE1":1356,"PHASE2":1358,"PHASE3":1360,"PHASE4":1362,"NA":1375},{"trials":1355,"activeCount":94},[],{"trials":1357,"activeCount":94},[],{"trials":1359,"activeCount":94},[],{"trials":1361,"activeCount":94},[],{"trials":1363,"activeCount":94},[1364],{"nctId":1365,"briefTitle":1366,"status":172,"phases":1367,"primaryCompletion":1368,"completion":1368,"start":1369,"enrollment":1370,"conditions":1371,"interventions":1373},"NCT02704091","Efficacy of Diosmectite (Smecta®) in the Symptomatic Treatment of Acute Diarrhoea in Adults",[87],"2019-04-08","2016-03-17",858,[1372],"Acute Diarrhoea",[1352,1374],"Smecta placebo",{"trials":1376,"activeCount":94},[],{"intervention":1374,"totalTrials":687,"cells":1378},{"EARLY_PHASE1":1379,"PHASE1":1381,"PHASE2":1383,"PHASE3":1385,"PHASE4":1387,"NA":1393},{"trials":1380,"activeCount":94},[],{"trials":1382,"activeCount":94},[],{"trials":1384,"activeCount":94},[],{"trials":1386,"activeCount":94},[],{"trials":1388,"activeCount":94},[1389],{"nctId":1365,"briefTitle":1366,"status":172,"phases":1390,"primaryCompletion":1368,"completion":1368,"start":1369,"enrollment":1370,"conditions":1391,"interventions":1392},[87],[1372],[1352,1374],{"trials":1394,"activeCount":94},[],{"intervention":1396,"totalTrials":687,"cells":1397},"Decapeptyl® SR 22.5mg",{"EARLY_PHASE1":1398,"PHASE1":1400,"PHASE2":1402,"PHASE3":1404,"PHASE4":1406,"NA":1416},{"trials":1399,"activeCount":94},[],{"trials":1401,"activeCount":94},[],{"trials":1403,"activeCount":94},[],{"trials":1405,"activeCount":94},[],{"trials":1407,"activeCount":94},[1408],{"nctId":1409,"briefTitle":1410,"status":277,"phases":1411,"primaryCompletion":504,"completion":504,"start":994,"enrollment":1412,"conditions":1413,"interventions":1414},"NCT01673984","GP Extended Action Triptorelin",[87],27,[18],[1396,1415],"Decapeptyl® SR 11.25mg; Prostap® 3 DCS 11.25mg; Zoladex® LA 10.8mg",{"trials":1417,"activeCount":94},[],{"intervention":1415,"totalTrials":687,"cells":1419},{"EARLY_PHASE1":1420,"PHASE1":1422,"PHASE2":1424,"PHASE3":1426,"PHASE4":1428,"NA":1434},{"trials":1421,"activeCount":94},[],{"trials":1423,"activeCount":94},[],{"trials":1425,"activeCount":94},[],{"trials":1427,"activeCount":94},[],{"trials":1429,"activeCount":94},[1430],{"nctId":1409,"briefTitle":1410,"status":277,"phases":1431,"primaryCompletion":504,"completion":504,"start":994,"enrollment":1412,"conditions":1432,"interventions":1433},[87],[18],[1396,1415],{"trials":1435,"activeCount":94},[],{"intervention":1437,"totalTrials":687,"cells":1438},"Tigan®",{"EARLY_PHASE1":1439,"PHASE1":1441,"PHASE2":1443,"PHASE3":1445,"PHASE4":1447,"NA":1460},{"trials":1440,"activeCount":94},[],{"trials":1442,"activeCount":94},[],{"trials":1444,"activeCount":94},[],{"trials":1446,"activeCount":94},[],{"trials":1448,"activeCount":94},[1449],{"nctId":1450,"briefTitle":1451,"status":172,"phases":1452,"primaryCompletion":1453,"completion":1454,"start":1455,"enrollment":1456,"conditions":1457,"interventions":1459},"NCT00489255","Safety\u002FEfficacy of Tigan® to Control Nausea\u002FVomiting Experienced During Apokyn® Initiation and Treatment",[87],"2011-12","2012-03","2007-05",117,[1458],"Parkinson's Disease",[1437],{"trials":1461,"activeCount":94},[],{"intervention":1463,"totalTrials":687,"cells":1464},"AboBoNT-A",{"EARLY_PHASE1":1465,"PHASE1":1467,"PHASE2":1469,"PHASE3":1471,"PHASE4":1473,"NA":1485},{"trials":1466,"activeCount":94},[],{"trials":1468,"activeCount":94},[],{"trials":1470,"activeCount":94},[],{"trials":1472,"activeCount":94},[],{"trials":1474,"activeCount":94},[1475],{"nctId":1476,"briefTitle":1477,"status":172,"phases":1478,"primaryCompletion":1479,"completion":1479,"start":1480,"enrollment":1481,"conditions":1482,"interventions":1483},"NCT04936542","A Study to Compare the Safety and Efficacy of Dysport® and Botox® in Adults With Upper Limb Spasticity.",[87],"2025-08-26","2021-06-23",464,[635],[1463,1484],"OnaBoNT-A",{"trials":1486,"activeCount":94},[],{"intervention":1484,"totalTrials":687,"cells":1488},{"EARLY_PHASE1":1489,"PHASE1":1491,"PHASE2":1493,"PHASE3":1495,"PHASE4":1497,"NA":1503},{"trials":1490,"activeCount":94},[],{"trials":1492,"activeCount":94},[],{"trials":1494,"activeCount":94},[],{"trials":1496,"activeCount":94},[],{"trials":1498,"activeCount":94},[1499],{"nctId":1476,"briefTitle":1477,"status":172,"phases":1500,"primaryCompletion":1479,"completion":1479,"start":1480,"enrollment":1481,"conditions":1501,"interventions":1502},[87],[635],[1463,1484],{"trials":1504,"activeCount":94},[],{"intervention":1506,"totalTrials":1163,"cells":1507},"lanreotide Autogel",{"EARLY_PHASE1":1508,"PHASE1":1510,"PHASE2":1512,"PHASE3":1524,"PHASE4":1546,"NA":1548},{"trials":1509,"activeCount":94},[],{"trials":1511,"activeCount":94},[],{"trials":1513,"activeCount":94},[1514],{"nctId":1515,"briefTitle":1516,"status":172,"phases":1517,"primaryCompletion":1518,"completion":1518,"start":1519,"enrollment":1520,"conditions":1521,"interventions":1522},"NCT02275338","Study to Assess Efficacy and Safety of Lanreotide Autogel 120 MG in Treatment of Clinical Symptoms Associated With Inoperable Malignant Intestinal Obstruction",[85],"2017-11-09","2014-11-19",52,[967],[1523],"Lanreotide Autogel",{"trials":1525,"activeCount":94},[1526,1535],{"nctId":1527,"briefTitle":1528,"status":277,"phases":1529,"completion":613,"start":1530,"enrollment":36,"conditions":1531,"interventions":1533},"NCT00092287","Comparison of Lanreotide Autogel® and Sandostatin LAR Depot in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome",[86],"2004-07",[1532],"Malignant Carcinoid Syndrome",[1506,1534],"Sandostatin long acting release",{"nctId":1536,"briefTitle":1537,"status":172,"phases":1538,"primaryCompletion":1539,"completion":1540,"start":1541,"enrollment":965,"conditions":1542,"interventions":1544},"NCT04852679","Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETs",[86],"2022-06-10","2023-01-13","2021-05-24",[1543],"Gastroenteropancreatic Neuroendocrine Tumor",[1545],"Lanreotide autogel",{"trials":1547,"activeCount":94},[],{"trials":1549,"activeCount":94},[],{"intervention":1551,"totalTrials":1163,"cells":1552},"Tasquinimod",{"EARLY_PHASE1":1553,"PHASE1":1555,"PHASE2":1557,"PHASE3":1581,"PHASE4":1592,"NA":1594},{"trials":1554,"activeCount":94},[],{"trials":1556,"activeCount":94},[],{"trials":1558,"activeCount":94},[1559,1569],{"nctId":1560,"briefTitle":1561,"status":277,"phases":1562,"primaryCompletion":1563,"completion":1564,"start":595,"enrollment":1565,"conditions":1566,"interventions":1568},"NCT01732549","A Proof of Concept Study of Maintenance Therapy With Tasquinimod in Patients With Metastatic Castrate-resistant Prostate Cancer Who Are Not Progressing After a First Line Docetaxel Based Chemotherapy",[85],"2015-02","2015-05",144,[1567],"Metastatic Castrate Resistant Prostate Cancer",[1551],{"nctId":1570,"briefTitle":1571,"status":172,"phases":1572,"primaryCompletion":467,"completion":1573,"start":665,"enrollment":1574,"conditions":1575,"interventions":1580},"NCT01743469","A Study With Tasquinimod Treating Patients With Hepatocellular, Ovarian, Renal Cell and Gastric Cancers",[85],"2016-04",201,[1576,1577,1578,1579],"Advanced or Metastatic Hepatocellular Cancer","Advanced or Metastatic Ovarian Cancer","Metastatic Renal Cell Cancer","Advanced or Metastatic Gastric Carcinoma",[1551,1551,1551,1551],{"trials":1582,"activeCount":94},[1583],{"nctId":1584,"briefTitle":1585,"status":277,"phases":1586,"primaryCompletion":1564,"completion":1564,"start":1587,"enrollment":1588,"conditions":1589,"interventions":1591},"NCT02057666","Study Of Tasquinimod In Asian Chemo-Naïve Patients With Metastatic Castrate-Resistant Prostate Cancer",[86],"2014-01",146,[1590],"Prostatic Neoplasms, Castration-Resistant",[1551],{"trials":1593,"activeCount":94},[],{"trials":1595,"activeCount":94},[],{"intervention":1597,"totalTrials":158,"cells":1598},"Palovarotene",{"EARLY_PHASE1":1599,"PHASE1":1601,"PHASE2":1612,"PHASE3":1614,"PHASE4":1626,"NA":1628},{"trials":1600,"activeCount":94},[],{"trials":1602,"activeCount":94},[1603],{"nctId":1604,"briefTitle":1605,"status":172,"phases":1606,"primaryCompletion":864,"completion":864,"start":888,"enrollment":1607,"conditions":1608,"interventions":1611},"NCT06908954","A Study of the Blood Levels of Palovarotene in Participants With Abnormal Liver Function Compared to Healthy Adult Participants After Intake of a Single Dose",[84],31,[1609,1610],"Hepatic Impairment","Healthy",[1597,1597,1597],{"trials":1613,"activeCount":94},[],{"trials":1615,"activeCount":94},[1616],{"nctId":1617,"briefTitle":1618,"status":172,"phases":1619,"primaryCompletion":1620,"completion":1620,"start":1621,"enrollment":1622,"conditions":1623,"interventions":1625},"NCT05027802","A Rollover Study to Further Evaluate the Safety and Efficacy of Palovarotene Capsules in Male and Female Participants Aged ≥14 Years With Fibrodysplasia Ossificans Progressiva (FOP) Who Have Completed the Relevant Parent Studies.",[86],"2024-11-30","2022-03-14",61,[1624],"Fibrodysplasia Ossificans Progressiva (FOP)",[1597],{"trials":1627,"activeCount":94},[],{"trials":1629,"activeCount":94},[],{"intervention":1631,"totalTrials":158,"cells":1632},"Triptorelin Pamoate",{"EARLY_PHASE1":1633,"PHASE1":1635,"PHASE2":1637,"PHASE3":1647,"PHASE4":1660,"NA":1662},{"trials":1634,"activeCount":94},[],{"trials":1636,"activeCount":94},[],{"trials":1638,"activeCount":94},[1639],{"nctId":1640,"briefTitle":1641,"status":172,"phases":1642,"primaryCompletion":1147,"completion":494,"start":1643,"enrollment":1644,"conditions":1645,"interventions":1646},"NCT01257425","Equivalence of Intramuscular (IM) Versus Subcutaneous (SC) Applications of Long Acting Pamorelin 11.25 mg",[85],"2010-12",109,[18],[1631],{"trials":1648,"activeCount":94},[1649],{"nctId":1650,"briefTitle":1651,"status":172,"phases":1652,"primaryCompletion":1653,"completion":1654,"start":1655,"enrollment":1656,"conditions":1657,"interventions":1659},"NCT05029622","A Study to Assess the Efficacy and Safety of the Triptorelin 6-month Formulation in Paediatric Participants With Central Precocious Puberty.",[86],"2022-08-21","2023-02-13","2021-08-10",66,[1658],"Central Precocious Puberty",[1631],{"trials":1661,"activeCount":94},[],{"trials":1663,"activeCount":94},[],{"intervention":1665,"totalTrials":158,"cells":1666},"Leucovorin",{"EARLY_PHASE1":1667,"PHASE1":1669,"PHASE2":1671,"PHASE3":1686,"PHASE4":1703,"NA":1705},{"trials":1668,"activeCount":94},[],{"trials":1670,"activeCount":94},[],{"trials":1672,"activeCount":94},[1673],{"nctId":1674,"briefTitle":1675,"status":172,"phases":1676,"primaryCompletion":1677,"completion":1677,"start":1678,"enrollment":1679,"conditions":1680,"interventions":1682},"NCT02551991","Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma",[85],"2021-02-15","2015-10-19",56,[1681],"Pancreatic Cancer",[1683,1684,1665,1685],"nal-IRI","5 fluorouracil","Oxaliplatin",{"trials":1687,"activeCount":94},[1688],{"nctId":1689,"briefTitle":1690,"status":172,"phases":1691,"primaryCompletion":1692,"completion":1693,"start":1694,"enrollment":1695,"conditions":1696,"interventions":1698},"NCT04083235","A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil\u002FLeucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment",[86],"2022-07-23","2025-02-18","2020-02-11",770,[1697],"Metastatic Adenocarcinoma of the Pancreas",[1699,1685,1700,1665,1701,1702],"Irinotecan Liposomal","5Fluorouracil","Nab-paclitaxel","Gemcitabine",{"trials":1704,"activeCount":94},[],{"trials":1706,"activeCount":94},[],{"intervention":1685,"totalTrials":158,"cells":1708},{"EARLY_PHASE1":1709,"PHASE1":1711,"PHASE2":1713,"PHASE3":1719,"PHASE4":1725,"NA":1727},{"trials":1710,"activeCount":94},[],{"trials":1712,"activeCount":94},[],{"trials":1714,"activeCount":94},[1715],{"nctId":1674,"briefTitle":1675,"status":172,"phases":1716,"primaryCompletion":1677,"completion":1677,"start":1678,"enrollment":1679,"conditions":1717,"interventions":1718},[85],[1681],[1683,1684,1665,1685],{"trials":1720,"activeCount":94},[1721],{"nctId":1689,"briefTitle":1690,"status":172,"phases":1722,"primaryCompletion":1692,"completion":1693,"start":1694,"enrollment":1695,"conditions":1723,"interventions":1724},[86],[1697],[1699,1685,1700,1665,1701,1702],{"trials":1726,"activeCount":94},[],{"trials":1728,"activeCount":94},[],{"intervention":1730,"totalTrials":158,"cells":1731},"Fortrans®",{"EARLY_PHASE1":1732,"PHASE1":1734,"PHASE2":1736,"PHASE3":1738,"PHASE4":1760,"NA":1762},{"trials":1733,"activeCount":94},[],{"trials":1735,"activeCount":94},[],{"trials":1737,"activeCount":94},[],{"trials":1739,"activeCount":94},[1740,1749],{"nctId":1741,"briefTitle":1742,"status":172,"phases":1743,"primaryCompletion":1044,"completion":1044,"start":524,"enrollment":1744,"conditions":1745,"interventions":1747},"NCT02321462","Efficacy, Safety and Tolerability of Eziclen in Adult Subjects Undergoing Colonoscopy",[86],296,[1746],"Bowel Cleansing",[1748,1730],"Eziclen",{"nctId":1750,"briefTitle":1751,"status":172,"phases":1752,"primaryCompletion":1753,"completion":1753,"start":1754,"enrollment":1755,"conditions":1756,"interventions":1758},"NCT03562884","Efficacy, Safety and Tolerability of a New Bowel Cleansing Preparation (BLI800) in Adult Subjects Undergoing Colonoscopy",[86],"2019-04-28","2018-07-01",297,[1757],"Diagnosis Disease",[1759,1730],"BLI800",{"trials":1761,"activeCount":94},[],{"trials":1763,"activeCount":94},[],{"intervention":1765,"totalTrials":158,"cells":1766},"Irinotecan liposome",{"EARLY_PHASE1":1767,"PHASE1":1769,"PHASE2":1784,"PHASE3":1786,"PHASE4":1800,"NA":1802},{"trials":1768,"activeCount":94},[],{"trials":1770,"activeCount":94},[1771],{"nctId":1772,"briefTitle":1773,"status":172,"phases":1774,"primaryCompletion":1775,"completion":1776,"start":1777,"enrollment":1778,"conditions":1779,"interventions":1781},"NCT05383352","A Study to Compare Onivyde Manufactured at Two Different Production Sites in Adult Participants With Advanced Cancer in the Pancreas",[84],"2024-05-27","2025-04-15","2022-05-30",177,[1780],"Metastatic Pancreatic Adenocarcinoma",[1765,1765,1765,1765,1782,1783],"Folinic Acid","5-Fluorouracil",{"trials":1785,"activeCount":94},[],{"trials":1787,"activeCount":94},[1788],{"nctId":1789,"briefTitle":1790,"status":172,"phases":1791,"primaryCompletion":1792,"completion":1793,"start":1794,"enrollment":1795,"conditions":1796,"interventions":1798},"NCT03088813","Study of Irinotecan Liposome Injection (ONIVYDE®) in Patients With Small Cell Lung Cancer",[86],"2022-02-08","2023-07-27","2018-04-25",491,[1797],"Small Cell Lung Cancer",[1765,1799],"Topotecan",{"trials":1801,"activeCount":94},[],{"trials":1803,"activeCount":94},[],{"intervention":1805,"totalTrials":158,"cells":1806},"Smecta (Diosmectite), duration of treatment - 7 days",{"EARLY_PHASE1":1807,"PHASE1":1809,"PHASE2":1811,"PHASE3":1813,"PHASE4":1831,"NA":1833},{"trials":1808,"activeCount":94},[],{"trials":1810,"activeCount":94},[],{"trials":1812,"activeCount":94},[],{"trials":1814,"activeCount":94},[1815,1824],{"nctId":1816,"briefTitle":1817,"status":172,"phases":1818,"primaryCompletion":1819,"completion":1819,"start":1229,"enrollment":1820,"conditions":1821,"interventions":1823},"NCT00352989","Effectiveness of Smecta in Combination With Oral Rehydration in the Treatment of Acute Watery Diarrhoea in Infants and Children",[86],"2007-03-24",302,[1822],"Diarrhoea",[1805],{"nctId":1825,"briefTitle":1826,"status":172,"phases":1827,"primaryCompletion":1828,"completion":1828,"start":1017,"enrollment":155,"conditions":1829,"interventions":1830},"NCT00352716","Effectiveness of Smecta in the Treatment of Acute Diarrhoea in Children",[86],"2007-02-01",[1822],[1805],{"trials":1832,"activeCount":94},[],{"trials":1834,"activeCount":94},[],{"intervention":1836,"totalTrials":158,"cells":1837},"Triptorelin Pamoate 11.25mg",{"EARLY_PHASE1":1838,"PHASE1":1840,"PHASE2":1842,"PHASE3":1844,"PHASE4":1864,"NA":1866},{"trials":1839,"activeCount":94},[],{"trials":1841,"activeCount":94},[],{"trials":1843,"activeCount":94},[],{"trials":1845,"activeCount":94},[1846,1854],{"nctId":1847,"briefTitle":1848,"status":172,"phases":1849,"primaryCompletion":1850,"completion":1850,"start":595,"enrollment":1851,"conditions":1852,"interventions":1853},"NCT01715129","Induction and Maintenance of Castration After Subcutaneous Injections of Triptorelin Pamoate in Patients With Prostate Cancer",[86],"2013-10",126,[18],[1836],{"nctId":1855,"briefTitle":1856,"status":172,"phases":1857,"primaryCompletion":1858,"completion":1858,"start":623,"enrollment":1859,"conditions":1860,"interventions":1862},"NCT00564850","Efficacy and Safety Study of Pamoate of Triptorelin in Children With Precocious Puberty",[86],"2010-10",37,[1861],"Precocious Puberty",[1863],"Triptorelin pamoate 11.25mg",{"trials":1865,"activeCount":94},[],{"trials":1867,"activeCount":94},[],{"intervention":1534,"totalTrials":687,"cells":1869},{"EARLY_PHASE1":1870,"PHASE1":1872,"PHASE2":1874,"PHASE3":1876,"PHASE4":1882,"NA":1884},{"trials":1871,"activeCount":94},[],{"trials":1873,"activeCount":94},[],{"trials":1875,"activeCount":94},[],{"trials":1877,"activeCount":94},[1878],{"nctId":1527,"briefTitle":1528,"status":277,"phases":1879,"completion":613,"start":1530,"enrollment":36,"conditions":1880,"interventions":1881},[86],[1532],[1506,1534],{"trials":1883,"activeCount":94},[],{"trials":1885,"activeCount":94},[],{"intervention":1887,"totalTrials":687,"cells":1888},"EGb761",{"EARLY_PHASE1":1889,"PHASE1":1891,"PHASE2":1893,"PHASE3":1895,"PHASE4":1908,"NA":1910},{"trials":1890,"activeCount":94},[],{"trials":1892,"activeCount":94},[],{"trials":1894,"activeCount":94},[],{"trials":1896,"activeCount":94},[1897],{"nctId":1898,"briefTitle":1899,"status":172,"phases":1900,"primaryCompletion":1901,"completion":1901,"start":301,"enrollment":1902,"conditions":1903,"interventions":1906},"NCT00276380","A Study on the Use of Tanakan® for Recovery of Neurological Impairment Following Ischaemic Stroke",[86],"2009-03",204,[1904,1905],"Stroke, Acute","Neurological Impairment",[1887,1907],"Acetylsalicylic acid",{"trials":1909,"activeCount":94},[],{"trials":1911,"activeCount":94},[],{"intervention":1907,"totalTrials":687,"cells":1913},{"EARLY_PHASE1":1914,"PHASE1":1916,"PHASE2":1918,"PHASE3":1920,"PHASE4":1926,"NA":1928},{"trials":1915,"activeCount":94},[],{"trials":1917,"activeCount":94},[],{"trials":1919,"activeCount":94},[],{"trials":1921,"activeCount":94},[1922],{"nctId":1898,"briefTitle":1899,"status":172,"phases":1923,"primaryCompletion":1901,"completion":1901,"start":301,"enrollment":1902,"conditions":1924,"interventions":1925},[86],[1904,1905],[1887,1907],{"trials":1927,"activeCount":94},[],{"trials":1929,"activeCount":94},[],{"intervention":1931,"totalTrials":687,"cells":1932},"Somatuline Autogel",{"EARLY_PHASE1":1933,"PHASE1":1935,"PHASE2":1937,"PHASE3":1939,"PHASE4":1949,"NA":1951},{"trials":1934,"activeCount":94},[],{"trials":1936,"activeCount":94},[],{"trials":1938,"activeCount":94},[],{"trials":1940,"activeCount":94},[1941],{"nctId":1942,"briefTitle":1943,"status":172,"phases":1944,"primaryCompletion":974,"completion":974,"start":1945,"enrollment":1946,"conditions":1947,"interventions":1948},"NCT00447499","Assessment of the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel",[86],"2007-04",59,[15],[1931],{"trials":1950,"activeCount":94},[],{"trials":1952,"activeCount":94},[],{"intervention":1954,"totalTrials":687,"cells":1955},"Triptorelin Pamoate PR 3-month",{"EARLY_PHASE1":1956,"PHASE1":1958,"PHASE2":1960,"PHASE3":1962,"PHASE4":1975,"NA":1977},{"trials":1957,"activeCount":94},[],{"trials":1959,"activeCount":94},[],{"trials":1961,"activeCount":94},[],{"trials":1963,"activeCount":94},[1964],{"nctId":1965,"briefTitle":1966,"status":172,"phases":1967,"primaryCompletion":1968,"completion":1969,"start":1970,"enrollment":155,"conditions":1971,"interventions":1973},"NCT03232281","Study to Compare the Oestradiol Suppression, Clinical Efficacy and Safety of Two Formulations of Triptorelin (Triptorelin Pamoate PR 3-month and Triptorelin Acetate PR 1-month) in Chinese Subjects With Endometriosis",[86],"2019-05-17","2019-11-16","2017-07-28",[1972],"Endometriosis",[1954,1974],"Triptorelin Acetate PR 1-month",{"trials":1976,"activeCount":94},[],{"trials":1978,"activeCount":94},[],{"intervention":1974,"totalTrials":687,"cells":1980},{"EARLY_PHASE1":1981,"PHASE1":1983,"PHASE2":1985,"PHASE3":1987,"PHASE4":1993,"NA":1995},{"trials":1982,"activeCount":94},[],{"trials":1984,"activeCount":94},[],{"trials":1986,"activeCount":94},[],{"trials":1988,"activeCount":94},[1989],{"nctId":1965,"briefTitle":1966,"status":172,"phases":1990,"primaryCompletion":1968,"completion":1969,"start":1970,"enrollment":155,"conditions":1991,"interventions":1992},[86],[1972],[1954,1974],{"trials":1994,"activeCount":94},[],{"trials":1996,"activeCount":94},[],{"intervention":1998,"totalTrials":687,"cells":1999},"Somatropin",{"EARLY_PHASE1":2000,"PHASE1":2002,"PHASE2":2004,"PHASE3":2006,"PHASE4":2020,"NA":2022},{"trials":2001,"activeCount":94},[],{"trials":2003,"activeCount":94},[],{"trials":2005,"activeCount":94},[],{"trials":2007,"activeCount":94},[2008],{"nctId":2009,"briefTitle":2010,"status":172,"phases":2011,"primaryCompletion":2012,"completion":2012,"start":1085,"enrollment":2013,"conditions":2014,"interventions":2019},"NCT00234533","Study to Define Optimal IGF-1 Monitoring in Children Treated With NutropinAq",[86],"2008-07",251,[2015,2016,2017,2018],"Turner Syndrome","Renal Insufficiency, Chronic","Pituitary Diseases","Dwarfism",[1998],{"trials":2021,"activeCount":94},[],{"trials":2023,"activeCount":94},[],{"intervention":2025,"totalTrials":687,"cells":2026},"lanreotide (Autogel formulation), duration of treatment 46-48 weeks",{"EARLY_PHASE1":2027,"PHASE1":2029,"PHASE2":2031,"PHASE3":2033,"PHASE4":2043,"NA":2045},{"trials":2028,"activeCount":94},[],{"trials":2030,"activeCount":94},[],{"trials":2032,"activeCount":94},[],{"trials":2034,"activeCount":94},[2035],{"nctId":2036,"briefTitle":2037,"status":172,"phases":2038,"completion":2039,"start":2040,"enrollment":1056,"conditions":2041,"interventions":2042},"NCT00499993","Efficacy and Tolerability of Lanreotide (Autogel 120 mg) in Patients With Acromegaly",[86],"2003-05","2001-01",[15],[2025],{"trials":2044,"activeCount":94},[],{"trials":2046,"activeCount":94},[],{"intervention":1748,"totalTrials":687,"cells":2048},{"EARLY_PHASE1":2049,"PHASE1":2051,"PHASE2":2053,"PHASE3":2055,"PHASE4":2061,"NA":2063},{"trials":2050,"activeCount":94},[],{"trials":2052,"activeCount":94},[],{"trials":2054,"activeCount":94},[],{"trials":2056,"activeCount":94},[2057],{"nctId":1741,"briefTitle":1742,"status":172,"phases":2058,"primaryCompletion":1044,"completion":1044,"start":524,"enrollment":1744,"conditions":2059,"interventions":2060},[86],[1746],[1748,1730],{"trials":2062,"activeCount":94},[],{"trials":2064,"activeCount":94},[],{"intervention":1799,"totalTrials":687,"cells":2066},{"EARLY_PHASE1":2067,"PHASE1":2069,"PHASE2":2071,"PHASE3":2073,"PHASE4":2079,"NA":2081},{"trials":2068,"activeCount":94},[],{"trials":2070,"activeCount":94},[],{"trials":2072,"activeCount":94},[],{"trials":2074,"activeCount":94},[2075],{"nctId":1789,"briefTitle":1790,"status":172,"phases":2076,"primaryCompletion":1792,"completion":1793,"start":1794,"enrollment":1795,"conditions":2077,"interventions":2078},[86],[1797],[1765,1799],{"trials":2080,"activeCount":94},[],{"trials":2082,"activeCount":94},[],{"intervention":2084,"totalTrials":687,"cells":2085},"rhIGF-1 (mecasermin) for a period of 86 weeks",{"EARLY_PHASE1":2086,"PHASE1":2088,"PHASE2":2090,"PHASE3":2092,"PHASE4":2102,"NA":2104},{"trials":2087,"activeCount":94},[],{"trials":2089,"activeCount":94},[],{"trials":2091,"activeCount":94},[],{"trials":2093,"activeCount":94},[2094],{"nctId":2095,"briefTitle":2096,"status":172,"phases":2097,"primaryCompletion":583,"completion":583,"start":585,"enrollment":248,"conditions":2098,"interventions":2101},"NCT00125190","Recombinant Human Insulin-Like Growth Factor (rhIGF-1) Treatment of Short Stature Associated With IGF-1 Deficiency",[85,86],[2099,2100],"Insulin-Like Growth Factor-1 Deficiency","Growth Disorders",[2084],{"trials":2103,"activeCount":94},[],{"trials":2105,"activeCount":94},[],{"intervention":2107,"totalTrials":687,"cells":2108},"rh IGF-1",{"EARLY_PHASE1":2109,"PHASE1":2111,"PHASE2":2113,"PHASE3":2115,"PHASE4":2126,"NA":2128},{"trials":2110,"activeCount":94},[],{"trials":2112,"activeCount":94},[],{"trials":2114,"activeCount":94},[],{"trials":2116,"activeCount":94},[2117],{"nctId":2118,"briefTitle":2119,"status":277,"phases":2120,"primaryCompletion":2121,"completion":2122,"start":2123,"enrollment":782,"conditions":2124,"interventions":2125},"NCT00330668","Treatment of Children and Adolescents With Growth Failure Associated With Primary IGF-1 Deficiency",[86],"2010-02","2010-03","2005-11",[2100],[2107],{"trials":2127,"activeCount":94},[],{"trials":2129,"activeCount":94},[],{"intervention":2131,"totalTrials":687,"cells":2132},"Triptorelin pamoate (embonate) salt",{"EARLY_PHASE1":2133,"PHASE1":2135,"PHASE2":2137,"PHASE3":2139,"PHASE4":2153,"NA":2155},{"trials":2134,"activeCount":94},[],{"trials":2136,"activeCount":94},[],{"trials":2138,"activeCount":94},[],{"trials":2140,"activeCount":94},[2141],{"nctId":2142,"briefTitle":2143,"status":172,"phases":2144,"primaryCompletion":2145,"completion":2145,"start":2146,"enrollment":2147,"conditions":2148,"interventions":2152},"NCT05590793","Effects of Triptorelin Pamoate 6-month When Given to Adult Chinese Participants With Advanced Cancer in the Prostate",[86],"2024-08-20","2022-11-17",195,[2149,2150,2151],"Advanced Prostate Cancer","Metastatic Prostate Cancer","Locally Advanced Prostate Cancer",[2131],{"trials":2154,"activeCount":94},[],{"trials":2156,"activeCount":94},[],{"intervention":1031,"totalTrials":687,"cells":2158},{"EARLY_PHASE1":2159,"PHASE1":2161,"PHASE2":2163,"PHASE3":2165,"PHASE4":2171,"NA":2173},{"trials":2160,"activeCount":94},[],{"trials":2162,"activeCount":94},[],{"trials":2164,"activeCount":94},[],{"trials":2166,"activeCount":94},[2167],{"nctId":1023,"briefTitle":1024,"status":277,"phases":2168,"primaryCompletion":1026,"completion":1026,"start":1027,"enrollment":9,"conditions":2169,"interventions":2170},[86],[1029],[1011,1031],{"trials":2172,"activeCount":94},[],{"trials":2174,"activeCount":94},[],{"intervention":2176,"totalTrials":687,"cells":2177},"Klean-Prep®",{"EARLY_PHASE1":2178,"PHASE1":2180,"PHASE2":2182,"PHASE3":2184,"PHASE4":2198,"NA":2200},{"trials":2179,"activeCount":94},[],{"trials":2181,"activeCount":94},[],{"trials":2183,"activeCount":94},[],{"trials":2185,"activeCount":94},[2186],{"nctId":2187,"briefTitle":2188,"status":172,"phases":2189,"primaryCompletion":2190,"completion":2191,"start":2192,"enrollment":2193,"conditions":2194,"interventions":2196},"NCT03008460","Efficacy, Safety and Tolerability of Eziclen®\u002FIzinova® Versus Klean-prep® on Bowel Cleansing in Adolescents Undergoing Colonoscopy",[86],"2020-02-24","2020-06-29","2017-10-15",250,[2195],"Digestive System Disease",[2197,2176],"Eziclen®\u002FIzinova®",{"trials":2199,"activeCount":94},[],{"trials":2201,"activeCount":94},[],{"intervention":1289,"totalTrials":687,"cells":2203},{"EARLY_PHASE1":2204,"PHASE1":2206,"PHASE2":2208,"PHASE3":2210,"PHASE4":2216,"NA":2218},{"trials":2205,"activeCount":94},[],{"trials":2207,"activeCount":94},[],{"trials":2209,"activeCount":94},[],{"trials":2211,"activeCount":94},[2212],{"nctId":1281,"briefTitle":1282,"status":172,"phases":2213,"primaryCompletion":1284,"completion":1284,"start":604,"enrollment":1285,"conditions":2214,"interventions":2215},[86],[1287],[1270,1289],{"trials":2217,"activeCount":94},[],{"trials":2219,"activeCount":94},[],{"intervention":1759,"totalTrials":687,"cells":2221},{"EARLY_PHASE1":2222,"PHASE1":2224,"PHASE2":2226,"PHASE3":2228,"PHASE4":2234,"NA":2236},{"trials":2223,"activeCount":94},[],{"trials":2225,"activeCount":94},[],{"trials":2227,"activeCount":94},[],{"trials":2229,"activeCount":94},[2230],{"nctId":1750,"briefTitle":1751,"status":172,"phases":2231,"primaryCompletion":1753,"completion":1753,"start":1754,"enrollment":1755,"conditions":2232,"interventions":2233},[86],[1757],[1759,1730],{"trials":2235,"activeCount":94},[],{"trials":2237,"activeCount":94},[],{"intervention":2239,"totalTrials":687,"cells":2240},"lanreotide (Autogel formulation), duration of treatment 24-56 weeks, depending on dose interval",{"EARLY_PHASE1":2241,"PHASE1":2243,"PHASE2":2245,"PHASE3":2247,"PHASE4":2256,"NA":2258},{"trials":2242,"activeCount":94},[],{"trials":2244,"activeCount":94},[],{"trials":2246,"activeCount":94},[],{"trials":2248,"activeCount":94},[2249],{"nctId":2250,"briefTitle":2251,"status":172,"phases":2252,"primaryCompletion":551,"completion":551,"start":330,"enrollment":2253,"conditions":2254,"interventions":2255},"NCT00444873","Effect of 120mg Somatuline Autogel at Different Dose Intervals (28, 42 or 56 Days) in Patients With Acromegaly",[86],38,[15],[2239],{"trials":2257,"activeCount":94},[],{"trials":2259,"activeCount":94},[],{"intervention":1255,"totalTrials":687,"cells":2261},{"EARLY_PHASE1":2262,"PHASE1":2264,"PHASE2":2266,"PHASE3":2268,"PHASE4":2274,"NA":2276},{"trials":2263,"activeCount":94},[],{"trials":2265,"activeCount":94},[],{"trials":2267,"activeCount":94},[],{"trials":2269,"activeCount":94},[2270],{"nctId":1247,"briefTitle":1248,"status":172,"phases":2271,"primaryCompletion":1250,"completion":1251,"start":594,"enrollment":1252,"conditions":2272,"interventions":2273},[86],[15],[1255,1256],{"trials":2275,"activeCount":94},[],{"trials":2277,"activeCount":94},[],{"intervention":2279,"totalTrials":687,"cells":2280},"mecasermin",{"EARLY_PHASE1":2281,"PHASE1":2283,"PHASE2":2285,"PHASE3":2287,"PHASE4":2299,"NA":2301},{"trials":2282,"activeCount":94},[],{"trials":2284,"activeCount":94},[],{"trials":2286,"activeCount":94},[],{"trials":2288,"activeCount":94},[2289],{"nctId":2290,"briefTitle":2291,"status":172,"phases":2292,"primaryCompletion":2293,"completion":2293,"start":2294,"enrollment":2295,"conditions":2296,"interventions":2298},"NCT00571727","Long-Term Treatment With rhIGF-1 in GHIS",[85,86],"2011-12-15","1991-05-20",92,[2297],"Growth Hormone Insensitivity Syndrome",[2279],{"trials":2300,"activeCount":94},[],{"trials":2302,"activeCount":94},[],{"intervention":2304,"totalTrials":687,"cells":2305},"rhIGF-1",{"EARLY_PHASE1":2306,"PHASE1":2308,"PHASE2":2310,"PHASE3":2312,"PHASE4":2322,"NA":2324},{"trials":2307,"activeCount":94},[],{"trials":2309,"activeCount":94},[],{"trials":2311,"activeCount":94},[],{"trials":2313,"activeCount":94},[2314],{"nctId":2315,"briefTitle":2316,"status":172,"phases":2317,"primaryCompletion":2012,"completion":2012,"start":2318,"enrollment":2319,"conditions":2320,"interventions":2321},"NCT00125164","Prepubertal Children With Growth Failure Associated With Primary Insulin-Like Growth Factor-1 (IGF-1) Deficiency",[86],"2004-03",137,[2100,2099],[2304],{"trials":2323,"activeCount":94},[],{"trials":2325,"activeCount":94},[],{"intervention":2327,"totalTrials":687,"cells":2328},"Lanreotide, non steroidal anti androgens and LHRH-a",{"EARLY_PHASE1":2329,"PHASE1":2331,"PHASE2":2333,"PHASE3":2335,"PHASE4":2344,"NA":2346},{"trials":2330,"activeCount":94},[],{"trials":2332,"activeCount":94},[],{"trials":2334,"activeCount":94},[],{"trials":2336,"activeCount":94},[2337],{"nctId":2338,"briefTitle":2339,"status":277,"phases":2340,"primaryCompletion":495,"completion":495,"start":399,"enrollment":1163,"conditions":2341,"interventions":2342},"NCT01313273","Study of Lanreotide in Non Metastatic Castration-resistant Prostate Cancer Patients",[86],[18],[2327,2343],"Non steroidal anti androgens and LHRH-a",{"trials":2345,"activeCount":94},[],{"trials":2347,"activeCount":94},[],{"intervention":2343,"totalTrials":687,"cells":2349},{"EARLY_PHASE1":2350,"PHASE1":2352,"PHASE2":2354,"PHASE3":2356,"PHASE4":2362,"NA":2364},{"trials":2351,"activeCount":94},[],{"trials":2353,"activeCount":94},[],{"trials":2355,"activeCount":94},[],{"trials":2357,"activeCount":94},[2358],{"nctId":2338,"briefTitle":2339,"status":277,"phases":2359,"primaryCompletion":495,"completion":495,"start":399,"enrollment":1163,"conditions":2360,"interventions":2361},[86],[18],[2327,2343],{"trials":2363,"activeCount":94},[],{"trials":2365,"activeCount":94},[],{"intervention":2367,"totalTrials":687,"cells":2368},"Triptorelin embonate 22.5 mg",{"EARLY_PHASE1":2369,"PHASE1":2371,"PHASE2":2373,"PHASE3":2375,"PHASE4":2386,"NA":2388},{"trials":2370,"activeCount":94},[],{"trials":2372,"activeCount":94},[],{"trials":2374,"activeCount":94},[],{"trials":2376,"activeCount":94},[2377],{"nctId":2378,"briefTitle":2379,"status":172,"phases":2380,"primaryCompletion":2381,"completion":2381,"start":2382,"enrollment":2383,"conditions":2384,"interventions":2385},"NCT05458856","Effects of Triptorelin When Given Every 6-months Under the Skin to Adult Males With Cancer in the Prostate",[86],"2024-07-08","2022-08-30",147,[18],[2367],{"trials":2387,"activeCount":94},[],{"trials":2389,"activeCount":94},[],{"intervention":2391,"totalTrials":687,"cells":2392},"Lanreotide microparticles",{"EARLY_PHASE1":2393,"PHASE1":2395,"PHASE2":2397,"PHASE3":2399,"PHASE4":2410,"NA":2412},{"trials":2394,"activeCount":94},[],{"trials":2396,"activeCount":94},[],{"trials":2398,"activeCount":94},[],{"trials":2400,"activeCount":94},[2401],{"nctId":2402,"briefTitle":2403,"status":172,"phases":2404,"primaryCompletion":604,"completion":604,"start":2405,"enrollment":2406,"conditions":2407,"interventions":2409},"NCT00729313","Efficacy and Safety of Lanreotide Versus Placebo for Treatment of Patients With Digestive Fistulae",[86],"2000-04",111,[2408],"Digestive Fistulae",[2391],{"trials":2411,"activeCount":94},[],{"trials":2413,"activeCount":94},[],{"intervention":1699,"totalTrials":687,"cells":2415},{"EARLY_PHASE1":2416,"PHASE1":2418,"PHASE2":2420,"PHASE3":2422,"PHASE4":2428,"NA":2430},{"trials":2417,"activeCount":94},[],{"trials":2419,"activeCount":94},[],{"trials":2421,"activeCount":94},[],{"trials":2423,"activeCount":94},[2424],{"nctId":1689,"briefTitle":1690,"status":172,"phases":2425,"primaryCompletion":1692,"completion":1693,"start":1694,"enrollment":1695,"conditions":2426,"interventions":2427},[86],[1697],[1699,1685,1700,1665,1701,1702],{"trials":2429,"activeCount":94},[],{"trials":2431,"activeCount":94},[],{"intervention":1700,"totalTrials":687,"cells":2433},{"EARLY_PHASE1":2434,"PHASE1":2436,"PHASE2":2438,"PHASE3":2440,"PHASE4":2446,"NA":2448},{"trials":2435,"activeCount":94},[],{"trials":2437,"activeCount":94},[],{"trials":2439,"activeCount":94},[],{"trials":2441,"activeCount":94},[2442],{"nctId":1689,"briefTitle":1690,"status":172,"phases":2443,"primaryCompletion":1692,"completion":1693,"start":1694,"enrollment":1695,"conditions":2444,"interventions":2445},[86],[1697],[1699,1685,1700,1665,1701,1702],{"trials":2447,"activeCount":94},[],{"trials":2449,"activeCount":94},[],{"intervention":1701,"totalTrials":687,"cells":2451},{"EARLY_PHASE1":2452,"PHASE1":2454,"PHASE2":2456,"PHASE3":2458,"PHASE4":2464,"NA":2466},{"trials":2453,"activeCount":94},[],{"trials":2455,"activeCount":94},[],{"trials":2457,"activeCount":94},[],{"trials":2459,"activeCount":94},[2460],{"nctId":1689,"briefTitle":1690,"status":172,"phases":2461,"primaryCompletion":1692,"completion":1693,"start":1694,"enrollment":1695,"conditions":2462,"interventions":2463},[86],[1697],[1699,1685,1700,1665,1701,1702],{"trials":2465,"activeCount":94},[],{"trials":2467,"activeCount":94},[],{"intervention":1702,"totalTrials":687,"cells":2469},{"EARLY_PHASE1":2470,"PHASE1":2472,"PHASE2":2474,"PHASE3":2476,"PHASE4":2482,"NA":2484},{"trials":2471,"activeCount":94},[],{"trials":2473,"activeCount":94},[],{"trials":2475,"activeCount":94},[],{"trials":2477,"activeCount":94},[2478],{"nctId":1689,"briefTitle":1690,"status":172,"phases":2479,"primaryCompletion":1692,"completion":1693,"start":1694,"enrollment":1695,"conditions":2480,"interventions":2481},[86],[1697],[1699,1685,1700,1665,1701,1702],{"trials":2483,"activeCount":94},[],{"trials":2485,"activeCount":94},[],{"intervention":2487,"totalTrials":687,"cells":2488},"Triptorelin pamoate 15mg",{"EARLY_PHASE1":2489,"PHASE1":2491,"PHASE2":2493,"PHASE3":2495,"PHASE4":2507,"NA":2509},{"trials":2490,"activeCount":94},[],{"trials":2492,"activeCount":94},[],{"trials":2494,"activeCount":94},[],{"trials":2496,"activeCount":94},[2497],{"nctId":2498,"briefTitle":2499,"status":172,"phases":2500,"primaryCompletion":2501,"completion":2502,"start":2503,"enrollment":2504,"conditions":2505,"interventions":2506},"NCT04736602","Efficacy and Safety Study of Triptorelin 3-Month Formulation in Chinese Children With Central Precocious Puberty.",[86],"2022-02-09","2022-09-03","2021-03-27",32,[1658],[2487],{"trials":2508,"activeCount":94},[],{"trials":2510,"activeCount":94},[],{"intervention":1077,"totalTrials":687,"cells":2512},{"EARLY_PHASE1":2513,"PHASE1":2515,"PHASE2":2517,"PHASE3":2519,"PHASE4":2525,"NA":2527},{"trials":2514,"activeCount":94},[],{"trials":2516,"activeCount":94},[],{"trials":2518,"activeCount":94},[],{"trials":2520,"activeCount":94},[2521],{"nctId":1070,"briefTitle":1071,"status":172,"phases":2522,"primaryCompletion":1004,"completion":1004,"start":1073,"enrollment":1074,"conditions":2523,"interventions":2524},[86],[15],[952,1077],{"trials":2526,"activeCount":94},[],{"trials":2528,"activeCount":94},[],{"intervention":2530,"totalTrials":36,"cells":2531},"BN83495",{"EARLY_PHASE1":2532,"PHASE1":2534,"PHASE2":2544,"PHASE3":2572,"PHASE4":2574,"NA":2576},{"trials":2533,"activeCount":94},[],{"trials":2535,"activeCount":94},[2536],{"nctId":2537,"briefTitle":2538,"status":172,"phases":2539,"primaryCompletion":1858,"completion":2540,"start":583,"enrollment":2541,"conditions":2542,"interventions":2543},"NCT00790374","BN83495 in Prostate Cancer",[84],"2011-02",17,[18],[2530,2530,2530],{"trials":2545,"activeCount":94},[2546,2558,2565],{"nctId":2547,"briefTitle":2548,"status":172,"phases":2549,"primaryCompletion":2550,"completion":2551,"start":2552,"enrollment":2553,"conditions":2554,"interventions":2556},"NCT00910091","The Study of Oral Steroid Sulphatase Inhibitor BN83495 Versus Megestrol Acetate (MA) in Women With Advanced or Recurrent Endometrial Cancer",[85],"2012-01","2013-07","2009-08",73,[2555],"Endometrial Cancer",[2530,2557],"Megestrol Acetate",{"nctId":2559,"briefTitle":2560,"status":277,"phases":2561,"primaryCompletion":399,"completion":506,"start":2562,"enrollment":31,"conditions":2563,"interventions":2564},"NCT01251354","Study of BN83495 in Post-menopausal Women With Endometrial Cancer Post-chemotherapy",[85],"2010-11",[2555],[2530],{"nctId":2566,"briefTitle":2567,"status":277,"phases":2568,"primaryCompletion":258,"completion":258,"start":258,"enrollment":158,"conditions":2569,"interventions":2571},"NCT01230970","Exploratory Study to Assess the Short Term Intratumoural and Peripheral Effects of BN83495 in Postmenopausal Women With Newly Diagnosed Breast Cancer",[85],[2570],"Breast Cancer",[2530],{"trials":2573,"activeCount":94},[],{"trials":2575,"activeCount":94},[],{"trials":2577,"activeCount":94},[],{"intervention":2579,"totalTrials":1163,"cells":2580},"Satoreotide trizoxetan",{"EARLY_PHASE1":2581,"PHASE1":2583,"PHASE2":2585,"PHASE3":2614,"PHASE4":2616,"NA":2618},{"trials":2582,"activeCount":94},[],{"trials":2584,"activeCount":94},[],{"trials":2586,"activeCount":94},[2587,2597,2606],{"nctId":2588,"briefTitle":2589,"status":277,"phases":2590,"primaryCompletion":2591,"completion":2591,"start":2592,"enrollment":25,"conditions":2593,"interventions":2595},"NCT03773133","Evaluate the Safety, Tolerability, Biodistribution and Anti Tumour Activity of 177LU-OPS201 With Companion Imaging 68Ga-OPS202 PET\u002FCT in Previously Treated Subjects With Locally Advanced or Metastatic Cancers Expressing Somatostatin Receptor 2 (SSTR2)",[84,85],"2019-10-10","2019-05-14",[2594],"Small Cell Lung Cancer and Breast Cancer",[2596,2579],"Satoreotide tetraxetan",{"nctId":2598,"briefTitle":2599,"status":172,"phases":2600,"primaryCompletion":2601,"completion":2601,"start":505,"enrollment":2602,"conditions":2603,"interventions":2604},"NCT02162446","68Ga-OPS202 Study for Diagnostic Imaging of GEP NET",[84,85],"2015-06",12,[1137],[2605],"satoreotide trizoxetan",{"nctId":2607,"briefTitle":2608,"status":277,"phases":2609,"primaryCompletion":2610,"completion":2610,"start":2611,"enrollment":36,"conditions":2612,"interventions":2613},"NCT03697551","Define the Optimal Uptake Time of 68Ga-OPS202 When Used as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Newly Diagnosed Breast Cancer",[85],"2019-02-06","2018-10-22",[2570],[2579],{"trials":2615,"activeCount":94},[],{"trials":2617,"activeCount":94},[],{"trials":2619,"activeCount":94},[],{"intervention":2596,"totalTrials":158,"cells":2621},{"EARLY_PHASE1":2622,"PHASE1":2624,"PHASE2":2626,"PHASE3":2639,"PHASE4":2641,"NA":2643},{"trials":2623,"activeCount":94},[],{"trials":2625,"activeCount":94},[],{"trials":2627,"activeCount":94},[2628,2635],{"nctId":2629,"briefTitle":2630,"status":277,"phases":2631,"primaryCompletion":2632,"completion":2632,"start":1027,"enrollment":586,"conditions":2633,"interventions":2634},"NCT02592707","Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201 in NETs",[84,85],"2022-02-22",[24],[2596],{"nctId":2588,"briefTitle":2589,"status":277,"phases":2636,"primaryCompletion":2591,"completion":2591,"start":2592,"enrollment":25,"conditions":2637,"interventions":2638},[84,85],[2594],[2596,2579],{"trials":2640,"activeCount":94},[],{"trials":2642,"activeCount":94},[],{"trials":2644,"activeCount":94},[],{"intervention":2646,"totalTrials":158,"cells":2647},"BIM 23A760",{"EARLY_PHASE1":2648,"PHASE1":2650,"PHASE2":2652,"PHASE3":2668,"PHASE4":2670,"NA":2672},{"trials":2649,"activeCount":94},[],{"trials":2651,"activeCount":94},[],{"trials":2653,"activeCount":94},[2654,2661],{"nctId":2655,"briefTitle":2656,"status":277,"phases":2657,"primaryCompletion":2540,"completion":2540,"start":2658,"enrollment":1644,"conditions":2659,"interventions":2660},"NCT00994214","Study to Assess the Efficacy and Safety of Repeated Administration of BIM 23A760 in Patients With Acromegaly",[85],"2009-10",[15],[2646],{"nctId":2662,"briefTitle":2663,"status":277,"phases":2664,"primaryCompletion":1643,"completion":2665,"start":2121,"enrollment":1086,"conditions":2666,"interventions":2667},"NCT01018953","Study to Assess the Efficacy and Safety of Different Doses of BIM 23A760 in Patients With Carcinoid Syndrome",[85],"2011-01",[1067],[2646],{"trials":2669,"activeCount":94},[],{"trials":2671,"activeCount":94},[],{"trials":2673,"activeCount":94},[],{"intervention":2675,"totalTrials":687,"cells":2676},"Lanreotide (Autogel formulation). Duration of treatment - 3 injections, 1 every 28 days",{"EARLY_PHASE1":2677,"PHASE1":2679,"PHASE2":2681,"PHASE3":2692,"PHASE4":2694,"NA":2696},{"trials":2678,"activeCount":94},[],{"trials":2680,"activeCount":94},[],{"trials":2682,"activeCount":94},[2683],{"nctId":2684,"briefTitle":2685,"status":277,"phases":2686,"primaryCompletion":1945,"completion":1945,"start":2687,"enrollment":2688,"conditions":2689,"interventions":2691},"NCT00288522","Lanreotide (Somatuline Autogel) in Thyroid-associated Ophthalmopathy Treatment",[85],"2006-01",5,[2690],"Thyroid-Associated Ophthalmopathy",[2675],{"trials":2693,"activeCount":94},[],{"trials":2695,"activeCount":94},[],{"trials":2697,"activeCount":94},[],{"intervention":2557,"totalTrials":687,"cells":2699},{"EARLY_PHASE1":2700,"PHASE1":2702,"PHASE2":2704,"PHASE3":2710,"PHASE4":2712,"NA":2714},{"trials":2701,"activeCount":94},[],{"trials":2703,"activeCount":94},[],{"trials":2705,"activeCount":94},[2706],{"nctId":2547,"briefTitle":2548,"status":172,"phases":2707,"primaryCompletion":2550,"completion":2551,"start":2552,"enrollment":2553,"conditions":2708,"interventions":2709},[85],[2555],[2530,2557],{"trials":2711,"activeCount":94},[],{"trials":2713,"activeCount":94},[],{"trials":2715,"activeCount":94},[],{"intervention":2717,"totalTrials":687,"cells":2718},"Lanreotide (Autogel formulation) and Temozolomide",{"EARLY_PHASE1":2719,"PHASE1":2721,"PHASE2":2723,"PHASE3":2733,"PHASE4":2735,"NA":2737},{"trials":2720,"activeCount":94},[],{"trials":2722,"activeCount":94},[],{"trials":2724,"activeCount":94},[2725],{"nctId":2726,"briefTitle":2727,"status":172,"phases":2728,"primaryCompletion":2729,"completion":2730,"start":534,"enrollment":586,"conditions":2731,"interventions":2732},"NCT02698410","Efficacy and Safety of Lanreotide Autogel (ATG) in Combination With Temozolomide in Subjects With Thoracic Neuroendocrine Tumors.",[85],"2019-02-08","2019-06-18",[986],[2717],{"trials":2734,"activeCount":94},[],{"trials":2736,"activeCount":94},[],{"trials":2738,"activeCount":94},[],{"intervention":2740,"totalTrials":687,"cells":2741},"BIM23B065",{"EARLY_PHASE1":2742,"PHASE1":2744,"PHASE2":2746,"PHASE3":2757,"PHASE4":2759,"NA":2761},{"trials":2743,"activeCount":94},[],{"trials":2745,"activeCount":94},[],{"trials":2747,"activeCount":94},[2748],{"nctId":2749,"briefTitle":2750,"status":277,"phases":2751,"primaryCompletion":2752,"completion":2753,"start":2754,"enrollment":36,"conditions":2755,"interventions":2756},"NCT03045302","Assessment of BIM23B065, Given as Repeated Subcutaneous Injection in Subjects With Acromegaly",[85],"2017-05-17","2017-06-02","2017-01-26",[15],[2740],{"trials":2758,"activeCount":94},[],{"trials":2760,"activeCount":94},[],{"trials":2762,"activeCount":94},[],{"intervention":2764,"totalTrials":687,"cells":2765},"NutropinAq®",{"EARLY_PHASE1":2766,"PHASE1":2768,"PHASE2":2770,"PHASE3":2783,"PHASE4":2785,"NA":2787},{"trials":2767,"activeCount":94},[],{"trials":2769,"activeCount":94},[],{"trials":2771,"activeCount":94},[2772],{"nctId":2773,"briefTitle":2774,"status":277,"phases":2775,"primaryCompletion":2776,"completion":1454,"start":2777,"enrollment":2778,"conditions":2779,"interventions":2781},"NCT00572156","rhGH and rhIGF-1 Combination Therapy in Children With Short Stature Associated With IGF-1 Deficiency",[85],"2010-04","2007-12",106,[2780],"Insulin-like Growth Factor-1 Deficiency",[2764,2782,2782,2782],"Increlex®",{"trials":2784,"activeCount":94},[],{"trials":2786,"activeCount":94},[],{"trials":2788,"activeCount":94},[],{"intervention":2782,"totalTrials":687,"cells":2790},{"EARLY_PHASE1":2791,"PHASE1":2793,"PHASE2":2795,"PHASE3":2801,"PHASE4":2803,"NA":2805},{"trials":2792,"activeCount":94},[],{"trials":2794,"activeCount":94},[],{"trials":2796,"activeCount":94},[2797],{"nctId":2773,"briefTitle":2774,"status":277,"phases":2798,"primaryCompletion":2776,"completion":1454,"start":2777,"enrollment":2778,"conditions":2799,"interventions":2800},[85],[2780],[2764,2782,2782,2782],{"trials":2802,"activeCount":94},[],{"trials":2804,"activeCount":94},[],{"trials":2806,"activeCount":94},[],{"intervention":2808,"totalTrials":687,"cells":2809},"Satoreotide trizoxetan 5-20μg",{"EARLY_PHASE1":2810,"PHASE1":2812,"PHASE2":2814,"PHASE3":2828,"PHASE4":2830,"NA":2832},{"trials":2811,"activeCount":94},[],{"trials":2813,"activeCount":94},[],{"trials":2815,"activeCount":94},[2816],{"nctId":2817,"briefTitle":2818,"status":172,"phases":2819,"primaryCompletion":2820,"completion":2821,"start":2822,"enrollment":2823,"conditions":2824,"interventions":2826},"NCT03220217","To Evaluate the Optimal Dose of 68Ga-OPS202 as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)",[85],"2019-07-25","2019-08-05","2017-09-26",29,[2825],"Gastro-Enteropancreatic Neuroendocrine Tumor",[2808,2827],"Satoreotide trizoxetan 30-45μg",{"trials":2829,"activeCount":94},[],{"trials":2831,"activeCount":94},[],{"trials":2833,"activeCount":94},[],{"intervention":2827,"totalTrials":687,"cells":2835},{"EARLY_PHASE1":2836,"PHASE1":2838,"PHASE2":2840,"PHASE3":2846,"PHASE4":2848,"NA":2850},{"trials":2837,"activeCount":94},[],{"trials":2839,"activeCount":94},[],{"trials":2841,"activeCount":94},[2842],{"nctId":2817,"briefTitle":2818,"status":172,"phases":2843,"primaryCompletion":2820,"completion":2821,"start":2822,"enrollment":2823,"conditions":2844,"interventions":2845},[85],[2825],[2808,2827],{"trials":2847,"activeCount":94},[],{"trials":2849,"activeCount":94},[],{"trials":2851,"activeCount":94},[],{"intervention":1683,"totalTrials":687,"cells":2853},{"EARLY_PHASE1":2854,"PHASE1":2856,"PHASE2":2858,"PHASE3":2864,"PHASE4":2866,"NA":2868},{"trials":2855,"activeCount":94},[],{"trials":2857,"activeCount":94},[],{"trials":2859,"activeCount":94},[2860],{"nctId":1674,"briefTitle":1675,"status":172,"phases":2861,"primaryCompletion":1677,"completion":1677,"start":1678,"enrollment":1679,"conditions":2862,"interventions":2863},[85],[1681],[1683,1684,1665,1685],{"trials":2865,"activeCount":94},[],{"trials":2867,"activeCount":94},[],{"trials":2869,"activeCount":94},[],{"intervention":1684,"totalTrials":687,"cells":2871},{"EARLY_PHASE1":2872,"PHASE1":2874,"PHASE2":2876,"PHASE3":2882,"PHASE4":2884,"NA":2886},{"trials":2873,"activeCount":94},[],{"trials":2875,"activeCount":94},[],{"trials":2877,"activeCount":94},[2878],{"nctId":1674,"briefTitle":1675,"status":172,"phases":2879,"primaryCompletion":1677,"completion":1677,"start":1678,"enrollment":1679,"conditions":2880,"interventions":2881},[85],[1681],[1683,1684,1665,1685],{"trials":2883,"activeCount":94},[],{"trials":2885,"activeCount":94},[],{"trials":2887,"activeCount":94},[],{"intervention":2889,"totalTrials":687,"cells":2890},"Triptorelin 22.5 mg",{"EARLY_PHASE1":2891,"PHASE1":2893,"PHASE2":2895,"PHASE3":2903,"PHASE4":2905,"NA":2907},{"trials":2892,"activeCount":94},[],{"trials":2894,"activeCount":94},[],{"trials":2896,"activeCount":94},[2897],{"nctId":2898,"briefTitle":2899,"status":277,"phases":2900,"primaryCompletion":467,"completion":467,"start":468,"enrollment":2504,"conditions":2901,"interventions":2902},"NCT01374087","Study to Assess the Efficacy of Brachytherapy With or Without Hormone Therapy, Using Triptorelin 22.5mg in Patients With Recurrence of Prostate Cancer",[85],[18],[2889],{"trials":2904,"activeCount":94},[],{"trials":2906,"activeCount":94},[],{"trials":2908,"activeCount":94},[],{"intervention":2910,"totalTrials":687,"cells":2911},"Diflomotecan",{"EARLY_PHASE1":2912,"PHASE1":2914,"PHASE2":2916,"PHASE3":2926,"PHASE4":2928,"NA":2930},{"trials":2913,"activeCount":94},[],{"trials":2915,"activeCount":94},[],{"trials":2917,"activeCount":94},[2918],{"nctId":2919,"briefTitle":2920,"status":172,"phases":2921,"primaryCompletion":2922,"completion":2922,"start":2923,"enrollment":25,"conditions":2924,"interventions":2925},"NCT00080015","Diflomotecan (BN80915) Administered Once Every 3 Weeks in Treating Patients With Sensitive Small Cell Lung Cancer (SCLC)",[85],"2005-02","2004-03-12",[1797],[2910],{"trials":2927,"activeCount":94},[],{"trials":2929,"activeCount":94},[],{"trials":2931,"activeCount":94},[],{"intervention":2933,"totalTrials":687,"cells":2934},"Lanreotide PRF",{"EARLY_PHASE1":2935,"PHASE1":2937,"PHASE2":2939,"PHASE3":2949,"PHASE4":2951,"NA":2953},{"trials":2936,"activeCount":94},[],{"trials":2938,"activeCount":94},[],{"trials":2940,"activeCount":94},[2941],{"nctId":2942,"briefTitle":2943,"status":172,"phases":2944,"primaryCompletion":2945,"completion":2945,"start":524,"enrollment":2946,"conditions":2947,"interventions":2948},"NCT02396953","Study to Determine the Maximum Tolerated Dose, Safety and Tolerability of a Single Dose of Lanreotide Prolonged Release Formulation (PRF) in Subjects With Acromegaly",[84,85],"2017-11-28",28,[15],[2933],{"trials":2950,"activeCount":94},[],{"trials":2952,"activeCount":94},[],{"trials":2954,"activeCount":94},[],{"intervention":2956,"totalTrials":687,"cells":2957},"EGb 761 120 mg",{"EARLY_PHASE1":2958,"PHASE1":2960,"PHASE2":2962,"PHASE3":2972,"PHASE4":2974,"NA":2976},{"trials":2959,"activeCount":94},[],{"trials":2961,"activeCount":94},[],{"trials":2963,"activeCount":94},[2964],{"nctId":2965,"briefTitle":2966,"status":172,"phases":2967,"primaryCompletion":458,"completion":458,"start":1094,"enrollment":2968,"conditions":2969,"interventions":2971},"NCT00824512","Efficacy of EGb761 in Patients Suffering From Friedreich Ataxia",[85],22,[2970],"Friedreich Ataxia",[2956],{"trials":2973,"activeCount":94},[],{"trials":2975,"activeCount":94},[],{"trials":2977,"activeCount":94},[],{"intervention":373,"totalTrials":687,"cells":2979},{"EARLY_PHASE1":2980,"PHASE1":2982,"PHASE2":2984,"PHASE3":2990,"PHASE4":2992,"NA":2994},{"trials":2981,"activeCount":94},[],{"trials":2983,"activeCount":94},[],{"trials":2985,"activeCount":94},[2986],{"nctId":364,"briefTitle":365,"status":172,"phases":2987,"primaryCompletion":367,"completion":367,"start":368,"enrollment":369,"conditions":2988,"interventions":2989},[85],[371],[373,47],{"trials":2991,"activeCount":94},[],{"trials":2993,"activeCount":94},[],{"trials":2995,"activeCount":94},[],{"intervention":2997,"totalTrials":687,"cells":2998},"BN82451B",{"EARLY_PHASE1":2999,"PHASE1":3001,"PHASE2":3003,"PHASE3":3014,"PHASE4":3016,"NA":3018},{"trials":3000,"activeCount":94},[],{"trials":3002,"activeCount":94},[],{"trials":3004,"activeCount":94},[3005],{"nctId":3006,"briefTitle":3007,"status":277,"phases":3008,"primaryCompletion":3009,"completion":3009,"start":3010,"enrollment":2541,"conditions":3011,"interventions":3013},"NCT02231580","Study Exploring Safety, Pharmacokinetic and Pharmacodynamic of BN82451 in Male Huntington's Disease Patients",[85],"2016-03-31","2014-09-01",[3012],"Huntington's Disease",[2997],{"trials":3015,"activeCount":94},[],{"trials":3017,"activeCount":94},[],{"trials":3019,"activeCount":94},[],{"intervention":1140,"totalTrials":687,"cells":3021},{"EARLY_PHASE1":3022,"PHASE1":3024,"PHASE2":3026,"PHASE3":3032,"PHASE4":3034,"NA":3036},{"trials":3023,"activeCount":94},[],{"trials":3025,"activeCount":94},[],{"trials":3027,"activeCount":94},[3028],{"nctId":1131,"briefTitle":1132,"status":172,"phases":3029,"primaryCompletion":485,"completion":1134,"start":594,"enrollment":1135,"conditions":3030,"interventions":3031},[85],[1137],[1139,1140],{"trials":3033,"activeCount":94},[],{"trials":3035,"activeCount":94},[],{"trials":3037,"activeCount":94},[],{"intervention":3039,"totalTrials":158,"cells":3040},"Telotristat etiprate",{"EARLY_PHASE1":3041,"PHASE1":3043,"PHASE2":3063,"PHASE3":3065,"PHASE4":3067,"NA":3069},{"trials":3042,"activeCount":94},[],{"trials":3044,"activeCount":94},[3045,3055],{"nctId":3046,"briefTitle":3047,"status":172,"phases":3048,"primaryCompletion":3049,"completion":3050,"start":3051,"enrollment":369,"conditions":3052,"interventions":3054},"NCT03442725","Study to Compare a Dose of Telotristat Etiprate in Subjects With Renal Impairment With Matched Subjects With Normal Renal Function",[84],"2018-04-27","2018-05-13","2018-02-09",[3053],"Renal Impairment",[3039],{"nctId":3056,"briefTitle":3057,"status":172,"phases":3058,"primaryCompletion":534,"completion":534,"start":3059,"enrollment":331,"conditions":3060,"interventions":3061},"NCT02683577","Study to Evaluate a Dose of Telotristat Etiprate in Male and Female With Mild, Moderate and Severe Hepatic Insufficiency and Matched Healthy Subjects",[84],"2016-02",[1609],[3062],"telotristat etiprate",{"trials":3064,"activeCount":94},[],{"trials":3066,"activeCount":94},[],{"trials":3068,"activeCount":94},[],{"trials":3070,"activeCount":94},[],{"intervention":3072,"totalTrials":687,"cells":3073},"Ferumoxytol",{"EARLY_PHASE1":3074,"PHASE1":3076,"PHASE2":3091,"PHASE3":3093,"PHASE4":3095,"NA":3097},{"trials":3075,"activeCount":94},[],{"trials":3077,"activeCount":94},[3078],{"nctId":3079,"briefTitle":3080,"status":172,"phases":3081,"primaryCompletion":3082,"completion":3082,"start":3083,"enrollment":248,"conditions":3084,"interventions":3089},"NCT01770353","MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment",[84],"2018-10-02","2012-11",[3085,3086,3087,3088],"Solid Tumors","ER\u002FPR Positive Breast Cancer","Triple Negative Breast Cancer","Metastatic Breast Cancer With Active Brain Metastasis",[3072,3090],"MM-398",{"trials":3092,"activeCount":94},[],{"trials":3094,"activeCount":94},[],{"trials":3096,"activeCount":94},[],{"trials":3098,"activeCount":94},[],{"intervention":3090,"totalTrials":687,"cells":3100},{"EARLY_PHASE1":3101,"PHASE1":3103,"PHASE2":3109,"PHASE3":3111,"PHASE4":3113,"NA":3115},{"trials":3102,"activeCount":94},[],{"trials":3104,"activeCount":94},[3105],{"nctId":3079,"briefTitle":3080,"status":172,"phases":3106,"primaryCompletion":3082,"completion":3082,"start":3083,"enrollment":248,"conditions":3107,"interventions":3108},[84],[3085,3086,3087,3088],[3072,3090],{"trials":3110,"activeCount":94},[],{"trials":3112,"activeCount":94},[],{"trials":3114,"activeCount":94},[],{"trials":3116,"activeCount":94},[],{"intervention":3118,"totalTrials":687,"cells":3119},"Irosustat",{"EARLY_PHASE1":3120,"PHASE1":3122,"PHASE2":3131,"PHASE3":3133,"PHASE4":3135,"NA":3137},{"trials":3121,"activeCount":94},[],{"trials":3123,"activeCount":94},[3124],{"nctId":3125,"briefTitle":3126,"status":172,"phases":3127,"primaryCompletion":3128,"completion":3128,"start":1945,"enrollment":1263,"conditions":3129,"interventions":3130},"NCT01840488","BN83495 Phase I in Post-menopausal Women",[84],"2010-09",[2570],[3118],{"trials":3132,"activeCount":94},[],{"trials":3134,"activeCount":94},[],{"trials":3136,"activeCount":94},[],{"trials":3138,"activeCount":94},[],{"intervention":3140,"totalTrials":687,"cells":3141},"IPN60090",{"EARLY_PHASE1":3142,"PHASE1":3144,"PHASE2":3157,"PHASE3":3159,"PHASE4":3161,"NA":3163},{"trials":3143,"activeCount":94},[],{"trials":3145,"activeCount":94},[3146],{"nctId":3147,"briefTitle":3148,"status":277,"phases":3149,"primaryCompletion":3150,"completion":3150,"start":3151,"enrollment":2968,"conditions":3152,"interventions":3153},"NCT03894540","Dose Escalation and Dose Expansion Study of IPN60090 in Patients With Advanced Solid Tumours",[84],"2020-12-21","2019-03-22",[919],[3140,3154,3155,3156],"pembrolizumab","paclitaxel","IPN60090 single administration",{"trials":3158,"activeCount":94},[],{"trials":3160,"activeCount":94},[],{"trials":3162,"activeCount":94},[],{"trials":3164,"activeCount":94},[],{"intervention":3154,"totalTrials":687,"cells":3166},{"EARLY_PHASE1":3167,"PHASE1":3169,"PHASE2":3175,"PHASE3":3177,"PHASE4":3179,"NA":3181},{"trials":3168,"activeCount":94},[],{"trials":3170,"activeCount":94},[3171],{"nctId":3147,"briefTitle":3148,"status":277,"phases":3172,"primaryCompletion":3150,"completion":3150,"start":3151,"enrollment":2968,"conditions":3173,"interventions":3174},[84],[919],[3140,3154,3155,3156],{"trials":3176,"activeCount":94},[],{"trials":3178,"activeCount":94},[],{"trials":3180,"activeCount":94},[],{"trials":3182,"activeCount":94},[],{"intervention":3155,"totalTrials":687,"cells":3184},{"EARLY_PHASE1":3185,"PHASE1":3187,"PHASE2":3193,"PHASE3":3195,"PHASE4":3197,"NA":3199},{"trials":3186,"activeCount":94},[],{"trials":3188,"activeCount":94},[3189],{"nctId":3147,"briefTitle":3148,"status":277,"phases":3190,"primaryCompletion":3150,"completion":3150,"start":3151,"enrollment":2968,"conditions":3191,"interventions":3192},[84],[919],[3140,3154,3155,3156],{"trials":3194,"activeCount":94},[],{"trials":3196,"activeCount":94},[],{"trials":3198,"activeCount":94},[],{"trials":3200,"activeCount":94},[],{"intervention":3156,"totalTrials":687,"cells":3202},{"EARLY_PHASE1":3203,"PHASE1":3205,"PHASE2":3211,"PHASE3":3213,"PHASE4":3215,"NA":3217},{"trials":3204,"activeCount":94},[],{"trials":3206,"activeCount":94},[3207],{"nctId":3147,"briefTitle":3148,"status":277,"phases":3208,"primaryCompletion":3150,"completion":3150,"start":3151,"enrollment":2968,"conditions":3209,"interventions":3210},[84],[919],[3140,3154,3155,3156],{"trials":3212,"activeCount":94},[],{"trials":3214,"activeCount":94},[],{"trials":3216,"activeCount":94},[],{"trials":3218,"activeCount":94},[],{"intervention":3220,"totalTrials":687,"cells":3221},"111In-IPN01087 Low dose",{"EARLY_PHASE1":3222,"PHASE1":3224,"PHASE2":3235,"PHASE3":3237,"PHASE4":3239,"NA":3241},{"trials":3223,"activeCount":94},[],{"trials":3225,"activeCount":94},[3226],{"nctId":3227,"briefTitle":3228,"status":972,"phases":3229,"primaryCompletion":3230,"completion":3230,"start":3231,"enrollment":94,"conditions":3232,"interventions":3233},"NCT04632199","Study to Assess the Safety and Efficacy of Intravenous Injection of the Imaging Agent 111In-IPN01087 in Patients With Locally Advanced or Metastatic Pancreatic or Colorectal Cancer.",[84],"2021-12-10","2021-03-12",[917,918],[3220,3234],"111In-IPN01087 High dose",{"trials":3236,"activeCount":94},[],{"trials":3238,"activeCount":94},[],{"trials":3240,"activeCount":94},[],{"trials":3242,"activeCount":94},[],{"intervention":3234,"totalTrials":687,"cells":3244},{"EARLY_PHASE1":3245,"PHASE1":3247,"PHASE2":3253,"PHASE3":3255,"PHASE4":3257,"NA":3259},{"trials":3246,"activeCount":94},[],{"trials":3248,"activeCount":94},[3249],{"nctId":3227,"briefTitle":3228,"status":972,"phases":3250,"primaryCompletion":3230,"completion":3230,"start":3231,"enrollment":94,"conditions":3251,"interventions":3252},[84],[917,918],[3220,3234],{"trials":3254,"activeCount":94},[],{"trials":3256,"activeCount":94},[],{"trials":3258,"activeCount":94},[],{"trials":3260,"activeCount":94},[],{"intervention":3262,"totalTrials":687,"cells":3263},"IPN59011",{"EARLY_PHASE1":3264,"PHASE1":3266,"PHASE2":3279,"PHASE3":3281,"PHASE4":3283,"NA":3285},{"trials":3265,"activeCount":94},[],{"trials":3267,"activeCount":94},[3268],{"nctId":3269,"briefTitle":3270,"status":277,"phases":3271,"primaryCompletion":3272,"completion":3272,"start":3273,"enrollment":1679,"conditions":3274,"interventions":3277},"NCT04736745","Study to Evaluate the Safety and Efficacy of IPN59011 in Improving the Appearance of Moderate to Severe Upper Facial Lines.",[84],"2022-10-28","2021-02-10",[3275,3276],"Moderate Upper Facial Lines","Severe Upper Facial Lines",[3262,3278],"Azzalure",{"trials":3280,"activeCount":94},[],{"trials":3282,"activeCount":94},[],{"trials":3284,"activeCount":94},[],{"trials":3286,"activeCount":94},[],{"intervention":3278,"totalTrials":687,"cells":3288},{"EARLY_PHASE1":3289,"PHASE1":3291,"PHASE2":3297,"PHASE3":3299,"PHASE4":3301,"NA":3303},{"trials":3290,"activeCount":94},[],{"trials":3292,"activeCount":94},[3293],{"nctId":3269,"briefTitle":3270,"status":277,"phases":3294,"primaryCompletion":3272,"completion":3272,"start":3273,"enrollment":1679,"conditions":3295,"interventions":3296},[84],[3275,3276],[3262,3278],{"trials":3298,"activeCount":94},[],{"trials":3300,"activeCount":94},[],{"trials":3302,"activeCount":94},[],{"trials":3304,"activeCount":94},[],{"intervention":3306,"totalTrials":687,"cells":3307},"177Lu-3BP-227",{"EARLY_PHASE1":3308,"PHASE1":3310,"PHASE2":3328,"PHASE3":3330,"PHASE4":3332,"NA":3334},{"trials":3309,"activeCount":94},[],{"trials":3311,"activeCount":94},[3312],{"nctId":3313,"briefTitle":3314,"status":277,"phases":3315,"primaryCompletion":3316,"completion":3317,"start":3318,"enrollment":3319,"conditions":3320,"interventions":3327},"NCT03525392","Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in Subjects With Solid Tumours Expressing Neurotensin Receptor Type 1.",[84],"2020-04-03","2021-04-28","2018-05-03",14,[917,918,3321,3322,3323,3324,3325,3326],"Gastric Cancer","Squamous Cell Carcinoma of the Head and Neck","Bone Cancer","Advanced Cancer","Recurrent Disease","Metastatic Tumours",[3306],{"trials":3329,"activeCount":94},[],{"trials":3331,"activeCount":94},[],{"trials":3333,"activeCount":94},[],{"trials":3335,"activeCount":94},[],{"intervention":3337,"totalTrials":687,"cells":3338},"BN80927",{"EARLY_PHASE1":3339,"PHASE1":3341,"PHASE2":3350,"PHASE3":3352,"PHASE4":3354,"NA":3356},{"trials":3340,"activeCount":94},[],{"trials":3342,"activeCount":94},[3343],{"nctId":3344,"briefTitle":3345,"status":172,"phases":3346,"primaryCompletion":623,"completion":623,"start":642,"enrollment":1679,"conditions":3347,"interventions":3349},"NCT01435096","BN80927 in Patients With Advanced Malignant Solid Tumors",[84],[3348],"Malignant Solid Tumour",[3337],{"trials":3351,"activeCount":94},[],{"trials":3353,"activeCount":94},[],{"trials":3355,"activeCount":94},[],{"trials":3357,"activeCount":94},[],{"intervention":1782,"totalTrials":687,"cells":3359},{"EARLY_PHASE1":3360,"PHASE1":3362,"PHASE2":3368,"PHASE3":3370,"PHASE4":3372,"NA":3374},{"trials":3361,"activeCount":94},[],{"trials":3363,"activeCount":94},[3364],{"nctId":1772,"briefTitle":1773,"status":172,"phases":3365,"primaryCompletion":1775,"completion":1776,"start":1777,"enrollment":1778,"conditions":3366,"interventions":3367},[84],[1780],[1765,1765,1765,1765,1782,1783],{"trials":3369,"activeCount":94},[],{"trials":3371,"activeCount":94},[],{"trials":3373,"activeCount":94},[],{"trials":3375,"activeCount":94},[],{"intervention":1783,"totalTrials":687,"cells":3377},{"EARLY_PHASE1":3378,"PHASE1":3380,"PHASE2":3386,"PHASE3":3388,"PHASE4":3390,"NA":3392},{"trials":3379,"activeCount":94},[],{"trials":3381,"activeCount":94},[3382],{"nctId":1772,"briefTitle":1773,"status":172,"phases":3383,"primaryCompletion":1775,"completion":1776,"start":1777,"enrollment":1778,"conditions":3384,"interventions":3385},[84],[1780],[1765,1765,1765,1765,1782,1783],{"trials":3387,"activeCount":94},[],{"trials":3389,"activeCount":94},[],{"trials":3391,"activeCount":94},[],{"trials":3393,"activeCount":94},[],{"intervention":3395,"totalTrials":2688,"cells":3396},"Triptorelin",{"EARLY_PHASE1":3397,"PHASE1":3399,"PHASE2":3401,"PHASE3":3411,"PHASE4":3434,"NA":3436},{"trials":3398,"activeCount":94},[],{"trials":3400,"activeCount":94},[],{"trials":3402,"activeCount":94},[3403],{"nctId":3404,"briefTitle":3405,"status":277,"phases":3406,"primaryCompletion":281,"completion":1094,"start":3407,"enrollment":3408,"conditions":3409,"interventions":3410},"NCT00444639","Study to Assess the Non-inferiority of Pamorelin® 11,25mg SC Injected Versus Pamorelin® 11,25mg IM Injected in Patients Suffering From Advanced Prostate Cancer (PAMOJECT)",[85],"2007-02",25,[18],[3395],{"trials":3412,"activeCount":94},[3413,3420,3427],{"nctId":3414,"briefTitle":3415,"status":172,"phases":3416,"primaryCompletion":468,"completion":495,"start":982,"enrollment":3417,"conditions":3418,"interventions":3419},"NCT01020448","Effect of Triptorelin (Decapeptyl®) 22.5 mg on Two Biomarkers in Patients With Advanced Prostate Cancer",[86],339,[18],[3395],{"nctId":3421,"briefTitle":3422,"status":172,"phases":3423,"primaryCompletion":398,"completion":3424,"start":612,"enrollment":8,"conditions":3425,"interventions":3426},"NCT00909844","Effects of Triptorelin Pamoate in Children With Precocious Puberty - Follow up Study",[86],"2016-01",[1861],[3395],{"nctId":3428,"briefTitle":3429,"status":277,"phases":3430,"completion":623,"start":3431,"enrollment":526,"conditions":3432,"interventions":3433},"NCT00415246","Study to Evaluate a Subcutaneous Four Months Sustained-release Formulation of Triptorelin in Patients With Prostate Cancer",[86],"2006-11",[18],[3395],{"trials":3435,"activeCount":94},[],{"trials":3437,"activeCount":94},[3438],{"nctId":3439,"briefTitle":3440,"status":172,"phases":3441,"primaryCompletion":3442,"completion":3442,"start":3443,"enrollment":3444,"conditions":3445,"interventions":3446},"NCT02238366","Study To Assess Renewal Of Treatment In Patients Recently Diagnosed With Prostate Cancer",[],"2019-06-06","2013-11",368,[18],[3447],"triptorelin",{"intervention":3449,"totalTrials":1163,"cells":3450},"Cabozantinib",{"EARLY_PHASE1":3451,"PHASE1":3453,"PHASE2":3455,"PHASE3":3479,"PHASE4":3481,"NA":3483},{"trials":3452,"activeCount":94},[],{"trials":3454,"activeCount":94},[],{"trials":3456,"activeCount":94},[3457,3468],{"nctId":3458,"briefTitle":3459,"status":277,"phases":3460,"primaryCompletion":154,"completion":154,"start":3461,"enrollment":3462,"conditions":3463,"interventions":3467},"NCT06341712","Effects of Maintenance Cabozantinib+BSC Versus BSC in Children and AYA With Osteosarcoma",[85],"2024-11-22",10,[3464,3465,3466],"Osteosarcoma","Osteosarcoma in Children","Osteosarcoma in Adolescents and Young Adults",[3449],{"nctId":3469,"briefTitle":3470,"status":172,"phases":3471,"primaryCompletion":3472,"completion":3473,"start":3474,"enrollment":3475,"conditions":3476,"interventions":3478},"NCT03945773","Study of Cabozantinib as 2nd Line Treatment in Subjects With Locally Advanced or Metastatic Renal Cell Carcinoma (RCC) With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors",[85],"2023-05-11","2026-02-12","2020-01-08",127,[3477],"Locally Advanced or Metastatic Renal Cell Carcinoma",[3449],{"trials":3480,"activeCount":94},[],{"trials":3482,"activeCount":94},[],{"trials":3484,"activeCount":94},[3485],{"nctId":3486,"briefTitle":3487,"status":172,"phases":3488,"primaryCompletion":3489,"completion":3489,"start":3490,"enrollment":3491,"conditions":3492,"interventions":3493},"NCT04637204","Real-world Treatment Patterns and Outcomes Among aRCC Patients on Cabozantinib or Axitinib in England",[],"2020-12-11","2020-11-24",1540,[33],[3449,3494],"Axitinib",{"intervention":2197,"totalTrials":158,"cells":3496},{"EARLY_PHASE1":3497,"PHASE1":3499,"PHASE2":3501,"PHASE3":3503,"PHASE4":3509,"NA":3511},{"trials":3498,"activeCount":94},[],{"trials":3500,"activeCount":94},[],{"trials":3502,"activeCount":94},[],{"trials":3504,"activeCount":94},[3505],{"nctId":2187,"briefTitle":2188,"status":172,"phases":3506,"primaryCompletion":2190,"completion":2191,"start":2192,"enrollment":2193,"conditions":3507,"interventions":3508},[86],[2195],[2197,2176],{"trials":3510,"activeCount":94},[],{"trials":3512,"activeCount":94},[3513],{"nctId":3514,"briefTitle":3515,"status":172,"phases":3516,"primaryCompletion":3517,"completion":3517,"start":390,"enrollment":3518,"conditions":3519,"interventions":3520},"NCT02630680","Eziclen Drug Utilisation in Real Life Setting",[],"2017-04-25",1286,[1746],[2197],{"intervention":3522,"totalTrials":158,"cells":3523},"EGb761®",{"EARLY_PHASE1":3524,"PHASE1":3526,"PHASE2":3528,"PHASE3":3540,"PHASE4":3542,"NA":3544},{"trials":3525,"activeCount":94},[],{"trials":3527,"activeCount":94},[],{"trials":3529,"activeCount":94},[3530],{"nctId":3531,"briefTitle":3532,"status":172,"phases":3533,"primaryCompletion":3534,"completion":3534,"start":1004,"enrollment":3535,"conditions":3536,"interventions":3539},"NCT00814346","Effect of EGb761® on Brain Glucose Metabolism in Three Groups of Elderly Defined by Cognitive Functions",[85],"2012-07",49,[3537,3538],"Alzheimer's Disease","Cognitive Impairment",[3522],{"trials":3541,"activeCount":94},[],{"trials":3543,"activeCount":94},[],{"trials":3545,"activeCount":94},[3546],{"nctId":3547,"briefTitle":3548,"status":172,"phases":3549,"primaryCompletion":398,"completion":398,"start":505,"enrollment":3550,"conditions":3551,"interventions":3553},"NCT02321475","EGb 761® (Tanakan®) Effectiveness in the Treatment of Patients of Middle Age and Younger With Psycho-emotional Symptoms, Added to Cognitive Disorders",[],54,[3552],"Cognitive Disorders",[3522],{"intervention":3494,"totalTrials":687,"cells":3555},{"EARLY_PHASE1":3556,"PHASE1":3558,"PHASE2":3560,"PHASE3":3562,"PHASE4":3564,"NA":3566},{"trials":3557,"activeCount":94},[],{"trials":3559,"activeCount":94},[],{"trials":3561,"activeCount":94},[],{"trials":3563,"activeCount":94},[],{"trials":3565,"activeCount":94},[],{"trials":3567,"activeCount":94},[3568],{"nctId":3486,"briefTitle":3487,"status":172,"phases":3569,"primaryCompletion":3489,"completion":3489,"start":3490,"enrollment":3491,"conditions":3570,"interventions":3571},[],[33],[3449,3494],{"intervention":3573,"totalTrials":687,"cells":3574},"Hexvix",{"EARLY_PHASE1":3575,"PHASE1":3577,"PHASE2":3579,"PHASE3":3581,"PHASE4":3583,"NA":3585},{"trials":3576,"activeCount":94},[],{"trials":3578,"activeCount":94},[],{"trials":3580,"activeCount":94},[],{"trials":3582,"activeCount":94},[],{"trials":3584,"activeCount":94},[],{"trials":3586,"activeCount":94},[3587],{"nctId":3588,"briefTitle":3589,"status":172,"phases":3590,"primaryCompletion":3591,"completion":3591,"start":2551,"enrollment":3592,"conditions":3593,"interventions":3595},"NCT02012036","Study To Optimize Photodynamic Transurethral Resection of the Bladder (TUR-B) In Clinical Practice",[],"2014-07",400,[3594],"Photodynamic Transurethral Resection of the Bladder (TUR-B)",[3573],{"intervention":3597,"totalTrials":687,"cells":3598},"Triptorelin Acetate 3.75mg intramuscular",{"EARLY_PHASE1":3599,"PHASE1":3601,"PHASE2":3603,"PHASE3":3605,"PHASE4":3607,"NA":3609},{"trials":3600,"activeCount":94},[],{"trials":3602,"activeCount":94},[],{"trials":3604,"activeCount":94},[],{"trials":3606,"activeCount":94},[],{"trials":3608,"activeCount":94},[],{"trials":3610,"activeCount":94},[3611],{"nctId":3612,"briefTitle":3613,"status":172,"phases":3614,"primaryCompletion":3615,"completion":3615,"start":3616,"enrollment":3617,"conditions":3618,"interventions":3620},"NCT01942369","A Study to Describe the Efficacy of Diphereline Following Conservative Surgery in Deep Infiltrating Endometriosis (DIE) Patients Over a Period of 24 Months",[],"2018-07-13","2013-09-16",402,[3619],"Deep Infiltrating Endometriosis (DIE)",[3597],{"intervention":3622,"totalTrials":687,"cells":3623},"Somatuline Autogel® (lanreotide) 60, 90, 120 mg.",{"EARLY_PHASE1":3624,"PHASE1":3626,"PHASE2":3628,"PHASE3":3630,"PHASE4":3632,"NA":3634},{"trials":3625,"activeCount":94},[],{"trials":3627,"activeCount":94},[],{"trials":3629,"activeCount":94},[],{"trials":3631,"activeCount":94},[],{"trials":3633,"activeCount":94},[],{"trials":3635,"activeCount":94},[3636],{"nctId":3637,"briefTitle":3638,"status":277,"phases":3639,"primaryCompletion":3640,"completion":3640,"start":3641,"enrollment":2688,"conditions":3642,"interventions":3643},"NCT02020499","Predictive Factors Study",[],"2015-09","2014-08",[15],[3622],{"intervention":3645,"totalTrials":687,"cells":3646},"Gonadotropin-releasing Hormone (GnRH) agonist therapy",{"EARLY_PHASE1":3647,"PHASE1":3649,"PHASE2":3651,"PHASE3":3653,"PHASE4":3655,"NA":3657},{"trials":3648,"activeCount":94},[],{"trials":3650,"activeCount":94},[],{"trials":3652,"activeCount":94},[],{"trials":3654,"activeCount":94},[],{"trials":3656,"activeCount":94},[],{"trials":3658,"activeCount":94},[3659],{"nctId":3660,"briefTitle":3661,"status":172,"phases":3662,"primaryCompletion":3663,"completion":3663,"start":390,"enrollment":3664,"conditions":3665,"interventions":3666},"NCT02630641","Perception of Cohesion Within a Relationship (Dyadic Adjustment) on the Quality of Life of Patients With Prostate Cancer With Gonadotropin-releasing Hormone.",[],"2017-11",1000,[18],[3645],{"intervention":3668,"totalTrials":687,"cells":3669},"Cabozantinib monotherapy",{"EARLY_PHASE1":3670,"PHASE1":3672,"PHASE2":3674,"PHASE3":3676,"PHASE4":3678,"NA":3680},{"trials":3671,"activeCount":94},[],{"trials":3673,"activeCount":94},[],{"trials":3675,"activeCount":94},[],{"trials":3677,"activeCount":94},[],{"trials":3679,"activeCount":94},[],{"trials":3681,"activeCount":94},[3682],{"nctId":3683,"briefTitle":3684,"status":172,"phases":3685,"primaryCompletion":3686,"completion":3686,"start":3687,"enrollment":3688,"conditions":3689,"interventions":3690},"NCT04353765","Study Of Cabozantinib Treatment In Patients With Unresectable, Locally Advanced Or Metastatic Renal Cell Carcinoma Who Progressed After Previous Treatment With Checkpoint Inhibitors",[],"2020-06-05","2020-01-30",247,[3477],[3668,3691],"All authorized TKI monotherapies in advanced RCC per FDA label in advanced RCC",{"intervention":3691,"totalTrials":687,"cells":3693},{"EARLY_PHASE1":3694,"PHASE1":3696,"PHASE2":3698,"PHASE3":3700,"PHASE4":3702,"NA":3704},{"trials":3695,"activeCount":94},[],{"trials":3697,"activeCount":94},[],{"trials":3699,"activeCount":94},[],{"trials":3701,"activeCount":94},[],{"trials":3703,"activeCount":94},[],{"trials":3705,"activeCount":94},[3706],{"nctId":3683,"briefTitle":3684,"status":172,"phases":3707,"primaryCompletion":3686,"completion":3686,"start":3687,"enrollment":3688,"conditions":3708,"interventions":3709},[],[3477],[3668,3691],{"intervention":3711,"totalTrials":687,"cells":3712},"LHRH analogues",{"EARLY_PHASE1":3713,"PHASE1":3715,"PHASE2":3717,"PHASE3":3719,"PHASE4":3721,"NA":3723},{"trials":3714,"activeCount":94},[],{"trials":3716,"activeCount":94},[],{"trials":3718,"activeCount":94},[],{"trials":3720,"activeCount":94},[],{"trials":3722,"activeCount":94},[],{"trials":3724,"activeCount":94},[3725],{"nctId":3726,"briefTitle":3727,"status":172,"phases":3728,"primaryCompletion":3729,"completion":3729,"start":3730,"enrollment":3731,"conditions":3732,"interventions":3733},"NCT03017313","To Evaluate the Criteria for Renewal of Luteinizing Hormone-Releasing Hormone (LHRH) Analogue Treatment in Prostate Cancer Patients",[],"2021-06-14","2017-07-13",510,[18],[3711],{"intervention":3735,"totalTrials":687,"cells":3736},"Somatuline Autogel® 60, 90 or 120 mg",{"EARLY_PHASE1":3737,"PHASE1":3739,"PHASE2":3741,"PHASE3":3743,"PHASE4":3745,"NA":3747},{"trials":3738,"activeCount":94},[],{"trials":3740,"activeCount":94},[],{"trials":3742,"activeCount":94},[],{"trials":3744,"activeCount":94},[],{"trials":3746,"activeCount":94},[],{"trials":3748,"activeCount":94},[3749],{"nctId":3750,"briefTitle":3751,"status":172,"phases":3752,"primaryCompletion":534,"completion":3753,"start":3754,"enrollment":3755,"conditions":3756,"interventions":3757},"NCT01840449","Somatuline Predictive Factors in Acromegaly and NET",[],"2017-05","2012-06",156,[15,986],[3735],{"intervention":3759,"totalTrials":687,"cells":3760},"Genetic analysis",{"EARLY_PHASE1":3761,"PHASE1":3763,"PHASE2":3765,"PHASE3":3767,"PHASE4":3769,"NA":3771},{"trials":3762,"activeCount":94},[],{"trials":3764,"activeCount":94},[],{"trials":3766,"activeCount":94},[],{"trials":3768,"activeCount":94},[],{"trials":3770,"activeCount":94},[],{"trials":3772,"activeCount":94},[3773],{"nctId":3774,"briefTitle":3775,"status":172,"phases":3776,"primaryCompletion":3777,"completion":3777,"start":1004,"enrollment":3778,"conditions":3779,"interventions":3780},"NCT00710307","Epidemiology Study on Insulin-like Growth Factor-1 in Children With Idiopathic Short Stature (EPIGROW Study)",[],"2010-01",275,[1323],[3759],{"intervention":3782,"totalTrials":687,"cells":3783},"mecasermin [rDNA origin]",{"EARLY_PHASE1":3784,"PHASE1":3786,"PHASE2":3788,"PHASE3":3790,"PHASE4":3792,"NA":3794},{"trials":3785,"activeCount":94},[],{"trials":3787,"activeCount":94},[],{"trials":3789,"activeCount":94},[],{"trials":3791,"activeCount":94},[],{"trials":3793,"activeCount":94},[],{"trials":3795,"activeCount":94},[3796],{"nctId":3797,"briefTitle":3798,"status":277,"phases":3799,"primaryCompletion":515,"completion":515,"start":1017,"enrollment":3800,"conditions":3801,"interventions":3803},"NCT00747604","IGFD Registry: A Patient Registry for Monitoring Long-term Safety and Efficacy of Increlex",[],1378,[3802],"Primary Insulin-like Growth Factor-1 Deficiency",[3782]]